Drug, bio-affecting and body treating compositions patents - Monitor Patents
FreshPatents.com Logo    FreshPatents.com icons
Monitor Keywords Patent Organizer File a Provisional Patent Browse Inventors Browse Industry Browse Agents



USPTO Class 514  |  Browse by Industry: Previous - Next | All     monitor keywords
10/2010 | Recent  |  14: Apr | Mar | Feb | Jan | 13: Dec | Nov | Oct | Sep | Aug | Jul | Jun | May | Apr | Mar | Feb | Jan | 12: Dec | Nov | Oct | Sep | Aug | July | June | May | April | Mar | Feb | Jan | 11: Dec | Nov | Oct | Sep | Aug | Jul | Jun | May | Apr | Mar | Feb | Jan | 10: Dec | Nov | Oct | Sep | Aug | Jul | Jun | May | Apr | Mar | Feb | Jan |  | 09: Dec | Nov | Oct | Sep | Aug | Jl | Jn | May | Apr | Mar | Fb | Jn |  | 2008 | 2007 |

Drug, bio-affecting and body treating compositions October categorized by USPTO classification 10/10

Below are recently published patent applications awaiting approval from the USPTO. Recent week's RSS XML file available below.
Listing for abstract view: USPTO application #, Title, Abstract excerpt,Patent Agent. Listing format for list view: USPTO National Class full category number, title of the patent application.
  
10/28/2010 > patent applications in patent subcategories. categorized by USPTO classification

20100273700 - Use of a peptide as a therapeutic agent: The present invention is directed to the use of the peptide compound Tyr-Gly-Gly-Phe-Leu-Arg-Arg-Gln-Phe-Lys-Val-Val-Thr-OH as a therapeutic agent for the prophylaxis and/or treatment of cancer, autoimmune diseases, fibrotic diseases, inflammatory diseases, neurodegenerative diseases, infectious diseases, lung diseases, heart and vascular diseases and metabolic diseases. Moreover the present invention relates to pharmaceutical... Agent: Winstead PC

20100273701 - Use of salusin beta alone or in combination with octreotide as a therapeutic agent: The present invention is directed to the use of the peptide compound Ala-lle-Phe-lle-Phe-lle-Arg-Trp-Leu-Leu-Lys-Leu-Gly-His-His-Gly-Arg-Ala-Pro-Pro-OH as a therapeutic agent for the prophylaxis and/or treatment of cancer, autoimmune diseases, fibrotic diseases, inflammatory diseases, neurodegenerative diseases, infectious diseases, lung diseases, heart and vascular diseases and metabolic diseases. Moreover the present invention relates to pharmaceutical... Agent: Winstead PC

20100273702 - Chimerical peptidic molecules with antiviral properties against the viruses of the flaviviridae family: The present invention is relative to chimerical peptides, whose primary structure holds at least one segment which inhibits the activation of the NS3 protease of a virus from the Flaviviridae family, they also contain a cell penetrating segment and they are capable of inhibiting or attenuate the viral infection. This... Agent: Hoffmann & Baron, LLP

20100273703 - Co-therapy for diabetic conditions: Methods of treating diseases such as diabetes are disclosed. Methods of modulating elevated fructosamine levels, elevated HbA1c levels, impaired glucose tolerance, and impaired fasting glucose are also disclosed. In some embodiments, methods include co-administration of a bile acid sequestrant and two or more additional compounds selected from the group consisting... Agent: Diehl Servilla LLC

20100273704 - Methods of modulating cellular homeostatic pathways and cellular survival: The invention provides composition and therapeutic, methods for modulating homeostatic pathways that are useful in treatment, and prevention of diabetes, diabetes associated disorders, metabolic disorders and cancer.... Agent: Wilson, Sonsini, Goodrich & Rosati

20100273705 - Method for inhibiting \"melanoma inhibitory activity\" mia: The present invention is directed to peptides, antibodies and antibody fragments inhibiting activity of “Melanoma Inhibitory Activity” (MIA).... Agent: Jacobson Holman PLLC

20100273706 - Injectable calcium phosphate solid rods and pastes for delivery of osteogenic proteins: Osteogenic proteins are delivered via an injectable solid rod or hardenable paste. The formulation comprises a calcium phosphate material, an osteogenic protein, and optional additives and active ingredients such as a bone resorption inhibitor. Methods of making injectable pharmaceutical compositions and methods of using the osteogenic compositions to treat bone... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20100273707 - Methods of inhibiting tumor cell aggressiveness using the microenvironment of human embryonic stem cells: The invention provides compositions comprising one or more isolated factors from a microenvironment of human embryonic stem cells (hESCs), including, but not limited to, Lefty and inhibitors of Nodal. The invention also provides methods of utilizing factors derived from human embryonic stem cells (hESC) and their microenvironment to treat and... Agent: Patton Boggs LLP

20100273708 - Adiponectin expression-inducing agents and uses thereof: The present invention provides adiponectin expression-inducing agents, and therapeutic agents using the same for obesity and obesity-related diseases such as cardiovascular diseases or metabolic diseases, as well as methods of searching for adiponectin expression-inducing agents. KLF9, which can bind to the 32-bp fragment of position −188 to position −157 from... Agent: Hunton & Williams LLP Intellectual Property Department

20100273709 - Composition comprising desmopressin: The present invention relates to a novel pharmaceutical composition as a solid dosage form comprising desmopressin as a therapeutically active ingredient. It addresses means for providing increased shelf-life for said active ingredient in said dosage form.... Agent: Foley And Lardner LLP Suite 500

20100273710 - Highly potent full and partial agonists and antagonists of the nociceptin/orphanin fq receptor: Peptide analogs of nociceptin/orphanin FQ, compositions thereof, and their use in treatment of disorders and dysfunctions related to activation or blocking of NOP receptors are described.... Agent: Abelman, Frayne & Schwab

20100273711 - Individualized cancer treatments: Provided herein are methods for the use of gene expression profiling to determine whether an individual afflicted with cancer will respond to a therapy, and in particular to therapeutic agents such as platinum-based agents and antimetabolite agents. Methods for the treatment of individuals with the therapeutic agents are also provided.... Agent: Michael Best & Friedrich LLP

20100273712 - Surfactant usage in lung transplantation and methods thereof: The present invention is directed to the use of pulmonary surfactants, and particularly pulmonary surfactants containing hydrophobic surfactant-associated proteins B, C or both (i.e., surfactants such as calfactant (Infasurf®), to treat PGD and other adverse effects of lung transplantation.... Agent: Paul T. Lavoie Jaeckle Fleischmann &mugel, LLP

20100273713 - Diagnosis and treatment of congenital heart defects using nell1: The present invention provides diagnostic methods for detecting congenital heart defects, or increased risk thereof, based on the Nell1 gene, RNA and protein. The methods include obtaining a biological sample and assessing the presence of a mutation in the Nell1 gene, RNA or protein. The presence of a mutation in... Agent: Ut-battelle, LLC Office Of Intellectual Property

20100273714 - Peptide compounds for treating refractory status epilepticus: The present invention is directed to the use of a class of peptide Compounds for prevention, alleviation or/and treatment of refractory Status epilepticus.... Agent: Harness, Dickey, & Pierce, P.l.c

20100273716 - New uses for amino acid anticonvulsants: e

20100273715 - Use of a peptide and an analgesic pharmaceutical agent: Inflammation caused by disease states such as rheumatism, gout, neurodegeneration and tumours result in the increased effectiveness of the opioid peptide biphalin or its analogues, due likely to the increased permeability of the “blood-brain barrier”, due to which it becomes possible to use the opioid peptide to produce a new... Agent: Cooper & Dunham, LLP

20100273717 - Use of an extract from the vigna aconitifolia plant in a cosmetic and/or dermopharmaceutical composition: An active composition for treating skin having a protein-containing extract from a Vigna aconitifolia plant.... Agent: Fox Rothschild LLP

20100273718 - Milk protein hydrolyzates with reduced immunogenic potential: Hydrolyzate compositions comprising at least one milk protein or whey hydrolyzed with at least one proteolytic enzyme are provided. The hydrolyzates reduce the immunogenicity of the milk or whey protein in a subject predisposed to having an immune reaction to the protein. Methods for making the compositions are also provided,... Agent: Steptoe & Johnson LLP

20100273719 - Use of somatostatin analogs in meningioma: The present invention relates to the use of a Somatostatin (SRIF) analog which has a high binding affinity to human SSTR1,2,3,5, or a pharmaceutically acceptable salt thereof for the preparation of a pharmaceutical composition for the treatment of meningioma.... Agent: Novartis Corporate Intellectual Property

20100273721 - Compositions and methods for treating ophthalmic disorders: The present invention relates to compositions and methods for treating ophthalmic disorders of humans or animals. The present compositions and methods are highly suitable for intraocular administration into the interior of an eye and provide therapeutic effects to the eye as they are effective in stabilizing, enhancing and/or improving a... Agent: Mccarter & English, LLP Boston

20100273720 - Protective complement proteins and age-related macular degeneration: Methods for identifying a subject at risk for developing AMD are disclosed. The methods include identifying specific protective or risk polymorphisms or genotypes from the subject's genetic material. Therapeutic compositions and methods are also provided for delaying the progression or onset of the development of AMD in a subject, including... Agent: Townsend And Townsend And Crew, LLP

20100273722 - Modified miniature proteins: The present invention generally relates to modified miniature proteins, including modified avian pancreatic polypeptides (aPP) and modified pancreatic peptide YYs (PYY). One aspect of the invention is generally directed to various aPPs that have been modified such that they do not substantially form multimers in solution, for example through the... Agent: Wolf Greenfield & Sacks, P.C.

20100273723 - Peptides of il-2: The present invention relates to new peptides of IL-2, derivatives thereof, and their use as therapeutic agents.... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, L.L.P.

20100273724 - Pegylated ion channel modulating compounds: This invention is directed to PEGlyated derivatives, drug conjugates and isotopic derivatives of certain ion channel modulating compounds. Pharmaceutical compositions and methods of use of also disclosed... Agent: Seed Intellectual Property Law Group PLLC

20100273725 - Novel compounds useful in therapeutic and cosmetic methods: The present invention relates to photosensitizer compounds for use in cosmetic and therapeutic applications of photodynamic therapy. The compounds of the present invention are designed for topical application and are characterized by a low permeability to the stratum corneum (the outer skin layer of an individual) and/or a low allergenic... Agent: Clifford W. Browning Krieg Devault LLP

20100273726 - Methicillin-resistant staphylococcus aureus active metabolites isolated from laurus nobilis and combinations thereof: This present provides kaempferol-3-(2-E,3-Z-di-p-coumaroyl)-rhamnoside, kaempferol-3-(2-Z-3-E-di-p-coumaroyl)-rhamnoside, and kaempferol-3-(2,3-di-Z-p-coumaroyl)-rhamnoside compounds useful as a new class of anti-bacterial agents. These compounds are extracted from Platanus occidentalis or Laurus nobilis. These compounds were found to exhibit anti-bacterial activity against methicillin resistant Staphylococcus aureus (MRSA).... Agent: Baker Donelson Bearman, Caldwell & Berkowitz, PC

20100273727 - Oral administration composition: An oral administration composition having a body fat reducing action and/or a neutral fat reducing action, which is a composition comprising a carotenoid and a sphingolipid or a carotenoid and a flavonoid and/or a derivative thereof, preferably a composition comprising a cryptoxanthin and a sphingolipid or a cryptoxanthin and a... Agent: Sughrue-265550

20100273728 - Formulations for the oral administration of therapeutic agents and related methods: The present application relates to an oral formulation of amphotericin B and other therapeutic agents, which formulation comprises one or more fatty acid glycerol esters and one or more PEG modified phospholipids or fatty acid esters. The formulation provides enhanced bioavailability and/or increased stability of the therapeutic agent at the... Agent: Bereskin And Parr LLP/s.e.n.c.r.l., S.r.l.

20100273729 - Compositions comprising compounds of natural origin for damaged skin: The present invention relates to a skin-protecting composition for the damaged skin, comprising glycyrrhizin, quercetin, rosmarinic acid, madecassic acid, chamazulene, bicalein and emodin. The composition of the present invention has all of excellent antioxidant, anti-inflammatory, wound-healing and moisturizing effects, thereby being widely used in medicine, cosmetic material or the like... Agent: Casimir Jones, S.c.

20100273854 - Compositions and methods for inhibiting nadph oxidase expression: One or more inhibitors, in particular siRNAs, which down-regulate the expression of a NOX gene selected from the group consisting of NOX4, NOXI, NOX2 (gp91phox, CYBB), NOX5, DUOX2, NOXOI, NOXAI and NOXA2 (p67phox) is disclosed. Also provided is a vector capable of expressing the compound A method is provided for... Agent: Cooper & Dunham, LLP

20100273855 - Compositions and methods of treating cancer: The invention features a method for treating cancer by administering a double-stranded nucleic acid molecule against a CX gene selected from the group consisting of C14orf78, MYBL2, UBE2S and UBE2T. The invention also features products, including the double-stranded nucleic acid molecules and vectors encoding them, as well as compositions comprising... Agent: Townsend And Townsend And Crew, LLP

20100273858 - Compositions comprising stat5 sirna and methods of use thereof: The present invention provides nucleic acid molecules that inhibit STAT5 expression. Methods of using the nucleic acid molecules are also provided.... Agent: Seed Intellectual Property Law Group PLLC

20100273860 - Modulation of apolipoprotein (a) expression: Compounds, compositions and methods are provided for modulating the expression of apolipoprotein(a). The compositions comprise oligonucleotides, targeted to nucleic acid encoding apolipoprotein(a). Methods of using these compounds for modulation of apolipoprotein(a) expression and for diagnosis and treatment of disease associated with expression of apolipoprotein(a) are provided.... Agent: Jones Day For Isis Pharmaceuticals, Inc.

20100273861 - Mycobacterial peptide deformylase: The present invention relates to the design of the Antisense-oligonucleotide complementary to the specific region of peptide deformylase gene from Mycobacterium tuberculosis. The use of this Antisense-oligonucleotide on mycobacterial culture inhibits the production of the peptide deformylase enzyme by hybridizing within the region, which is found to be responsible for... Agent: Harness, Dickey & Pierce, P.L.C

20100273856 - Screening of micro-rna cluster inhibitor pools: The disclosure provides methods for inhibiting the activity of a miRNA cluster in a cell, and also for screening a cell for a phenotype(s) of interest resulting from inhibition of a miRNA cluster. The methods use a cluster pool which comprises at least one miRNA inhibitor specific for each miRNA... Agent: Merchant & Gould PC

20100273857 - Suppression of scn9a gene expression and/or function for the treatment of pain: Disclosed herein are methods, sequences and nucleic acid molecules used to treat pain. Specifically, the methods and sequences include locally administering molecules that suppress the expression of amino acid sequences that encode for Nav1.7 channels or that otherwise inhibit the function of Nav1.7 channels. Local suppression of Nav1.7 channel levels... Agent: K&l Gates LLP

20100273859 - Treatment and prevention of hiv infection: Disclosed herein are methods for treating and/or preventing HIV infection in a cell. The methods involve downmodulating one or more of the HIV-dependency factors (HDFs) disclosed herein to thereby treat and/or prevent HIV infection in the cell. Downmodulating the HDFs can be by contacting the cell with an agent that... Agent: David S. Resnick

20100273864 - Controlled release auris sensory cell modulator compositions and methods for the treatment of otic disorders: Disclosed herein are compositions and methods for the treatment of otic diseases or conditions with auris sensory cell modulating agent compositions and formulations administered locally to an individual afflicted with an otic disease or condition, through direct application of these compositions and formulations onto or via perfusion into the targeted... Agent: Wilson, Sonsini, Goodrich & Rosati

20100273866 - Diagnosis and treatment of cancer: i: A method of diagnosing cancer comprising the steps of (i) obtaining a sample containing nucleic acid and/or protein from the patient; and (ii) determining whether the sample contains a level of SCN5A (and optionally also SCN9A) voltage-gated Na+ channel nucleic acid or protein associated with cancer. A method of diagnosing... Agent: Nikolai & Mersereau, P.A.

20100273863 - Modulation of gene expression using oligomers that target gene regions downstream of 3' untranslated regions: Gene expression can be selectively modulated by contacting a cell with an oligomer that targets a gene region downstream of a ′3-UTR, thereby increasing or decreasing the expression of the target gene.... Agent: Fulbright & Jaworski L.L.P.

20100273862 - Phosphatases which activate map kinase pathways: The present invention provides novel JNK activating phosphatase polypeptides and nucleic acid molecules encoding the same. The invention also provides vectors, host cells, antibodies and methods for producing JNK activating phosphatase polypeptides. Also provided for are methods for the diagnosis and treatment of diseases associated with JNK activating phosphatase polypeptides.... Agent: Mcdonnell Boehnen Hulbert & Berghoff LLP

20100273865 - Polypeptides involved in neuronal regeneration-associated gene expression: The present invention relates to methods for promoting regeneration response of peripheral and central nervous systems in mammals in need of such biological effects. The methods comprise altering the activity or steady state level of specific transcription factors that control regeneration of injured or degenerated neuronal cells. Preferably the activity... Agent: Edwards Angell Palmer & Dodge LLP

20100273867 - Therapy-enhancing glucan: A therapeutic composition for treatment of cancer in a mammal is disclosed. The composition comprises an effective amount of a glucan composition which is suitable for oral administration and for absorption through the gastrointestinal tract of the mammal, and at least one antibody for the cancer. A method of treating... Agent: Law Offices Of Albert Wai-kit Chan, PLLC

20100273732 - Combination methods of treating cancer: The present invention relates to a method of treating cancer in a subject in need thereof, by administering to a subject in need thereof a first amount of a histone deacetylase (HDAC) inhibitor or a pharmaceutically acceptable salt or hydrate thereof, in a first treatment procedure, and a second amount... Agent: Mintz Levin Cohn Ferris Glovsky And Popeo, P.C.

20100273731 - Medium-chain length fatty acids, salts and triglycerides in combination with gemcitabine for treatment of pancreatic cancer: The present invention relates to the use of medium-chain length fatty acids of formula I, triglycerides of formula 2 (wherein n=6-10), salts thereof, or mixtures thereof, in combination with gemcitabine and optionally erlotinib in the treatment of pancreatic cancer in human patients. Exemplary medium-chain length fatty acid/triglyceride compounds include capric... Agent: Clark & Elbing LLP

20100273730 - Self-emulsifying pharmaceutical compositions of hydrophilic drugs and preparation thereof: The present invention provides an oral self micro-emulsifying pharmaceutical composition of a hydrophilic drug or a pharmaceutically acceptable salt thereof which, in addition to the hydrophilic drug, one or more solvents for solving the hydrophilic drug to form a drug-solvent solution and a surfactant system, further comprises one or more... Agent: Volpe And Koenig, P.C.

20100273733 - Hiv treatment: The invention is directed to a method of treating an HIV infection comprising administering an aminoalkanol and a glucocorticoid. The invention is also directed to a pharmaceutical composition comprising the aminoalkanol and the glucocorticoid in amounts effective to selectively eliminate HIV-infected cells and/or to inhibit HIV replication. A method of... Agent: Murphy Desmond S.c.

20100273736 - Cosmetic composition comprising glycogen for skin application with velvet effect: This invention relates to a cosmetic composition for skin application having a velvet effect on the skin comprising, as the cosmetic active ingredient, a glycogen having less than 1,000 ppm of nitrogen and less than 1% by weight of reducing sugars, in at least one cosmetically-acceptable vehicle.... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, L.L.P.

20100273734 - Derivatives of hyaluronic acids: The present invention relates to methods for preparing a derivative of a hyaluronic acid, comprising: (a) mixing a liquid solution comprising the hyaluronic acid and a diamine, a polyamine, or a combination thereof, at a pH suitable to form an imine; (b) reducing the imine to an amine with a... Agent: Novozymes, Inc.

20100273735 - Soluble, highly branched glucose polymers for enteral and parenteral nutrition and for peritoneal dialysis: The invention relates to soluble, highly branched glucose polymers which are obtained by enzymatic treatment of starch, having a reducing sugars content of less than 3.5%, exhibiting a proportion of α-1,6-glucosidic linkages of between 20% and 30%, a Mw, determined by light scattering, of between 20·103 and 30·103 daltons, and... Agent: Young & Thompson

20100273737 - Supplementary food composition for reducing body odor: A food supplement for reducing body odor which includes a mixture of edible carriers with chitin aqueous solution lyophilized powder, chitosan aqueous solution lyophilized powder, chitin powder, chitosan powder, or a combination of these ingredients, in the form of tablets or pills. The food supplement has the outstanding effect of... Agent: Birch Stewart Kolasch & Birch

20100273738 - Integrated patient management and control system for medication delivery: An integrated patient monitoring and control system is provided which includes a closed-loop control system for monitoring and adjusting the heparin infusion rate for a patient. The system includes a processor which uses a dynamic patient model that is continuously adjusted based on the patient's aPTT measurements to calculate an... Agent: O''melveny & Myers LLP Ip&t Calendar Department La-13-a7

20100273739 - Aminotetraline derivatives, pharmaceutical composition, containing them, and their use in therapy:

20100273740 - Phospholipids for the treatment of infection by togaviruses, herpes viruses and coronaviruses: Provided are compounds, methods and pharmaceutical compositions for treating a host, especially a human, infected with a togavirus, herpes virus and/or coronavirus, and in particular SARS-CoV, cytomegalovirus or varicella-zoster virus. The method in one embodiment comprises administering to that host an effective amount of an anti-togavirus, anti-herpes virus and/or anti-coronavirus... Agent: Morgan Lewis & Bockius LLP

20100273741 - Apparatus and methods for adipose tissue detection: The present invention finds application in the field of cosmetic medicine and particularly relates to an apparatus for adipose tissue detection which comprises a first electronic circuit for generating a beam of electromagnetic waves, radiating means for orienting the beam to an adipose tissue-containing part, sensor means for detecting reflected... Agent: Themis Law

20100273742 - Pharmacologically active agents containing esterified phosphonates and methods for use thereof: Compounds and compositions are provided for treatment, prevention, or amelioration of a variety of medical disorders associated with viral infections, cell proliferation and bone metabolism. The compounds provided herein are alkyl esters of phosphonates.... Agent: Jones Day

20100273743 - Morpholin-4-ium 4 methoxyphenyl (morpholino) phosphinodithioate (gyy4137) as a novel vasodilator agent: m

20100273744 - Compounds: The present invention relates to amide compounds, processes for their preparation, pharmaceutical compositions containing these compounds and to their use in the treatment of disorders, conditions or disorders such as allergic disorders, inflammatory disorders and disorders of the immune system.... Agent: Glaxosmithkline Global Patents -us, Uw2220

20100273745 - Polyamines useful as anti-parasitic and anti-cancer therapeutics and as lysine-specific demethylase inhibitors: Polyamine, polyamine/guanidino, and polyamine/biguanide compounds are disclosed. The compounds are useful as anti-cancer and anti-parasitic treatments. The compounds are also useful as inhibitors of the enzyme lysine-specific demethylase-1.... Agent: Edwards Angell Palmer & Dodge LLP

20100273746 - Pharmaceutical formulations containing tolperisone: The present invention relates to pharmaceutical formulation containing tolperisone or its pharmaceutically acceptable salts or tolperisone combined with a non-steroidal anti-inflammatory drug or their salts, gel forming macromolecule, solvent, and if required thickening agent, penetration enhancer and pH adjuvant or the mixture thereof. The invention also relates to the manufacturing... Agent: Hahn & Voight PLLC

20100273747 - Freeze-dried composition of active substances: The invention relates to freeze-dried molded articles, containing ≧50% by wt. of one or more active substances, and >15% by wt. of one or more scaffold-forming agents, with proteins being excepted, as well as optionally one or more auxiliary substances, in each case based on the total composition of the... Agent: Dilworth & Barrese, LLP

20100273748 - Antimicrobial therapy: Methods and compositions for modulating gene expression and the innate immune response by 1,25(OH)2 vitamin D3 (1,25D3) are provided. Also provided are methods and compositions for modulating histone acetylation using 1,25(OH)2 vitamin D3 (1,25D3).... Agent: Joseph R. Baker, Apc Gavrilovich, Dodd & Lindsey LLP

20100273756 - Adjunctive formulation and methods for palliation of fine wrinkles, mottled hyperpigmentation, tactile roughness of facial skin and related disorders: The present invention is generally directed to the treatment of fine wrinkles, hyperpigmentation, roughness of facial skin, improvement of photoaging, repair of sun damaged skin, and related disorders. In a formulation aspect, the present invention provides a formulation for the adjunct treatment of skin disorders, where the formulation includes tretinoin... Agent: Karen S. Canady Canady & Lortz LLP

20100273755 - Diamide compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity: e

20100273752 - Mequitazine for treating or preventing pathologies involving histamine h4 receptors: The present application relates to the use of 10-[(3R)-1-azabicyclo[2.2.2]oct-3-ylmethyl]-10H-phenothiazine, 10-[(3S)-1-azabicyclo[2.2.2]oct-3-ylmethyl]-10H-phenothiazine or 10-[(3R,3S)-1-azabicyclo[2.2.2]oct-3-ylmethyl]-10H-phenothiazine, or a pharmaceutically acceptable salt thereof, to prepare a drug to prevent or treat pathologies involving histamine H4 receptor.... Agent: Birch Stewart Kolasch & Birch

20100273749 - Method for treating dry-eye syndrome: The subject application provides an aqueous composition suitable for use as an artificial tear solution comprising one or more lipids produced by an enzyme of the diacylglycerol acyltransferase 2 (DGAT2) family and/or the acyl-CoA cholesterol acytransferase (ACAT) family. This invention also provides related methods.... Agent: Cooper & Dunham, LLP

20100273753 - Organic compounds: 1- or 2- or 7-(substituted)-3-(optionally hetero)arylamino-[1H, 2H]-pyrazolo[3,4-d] pyrimidine-4,6(5H, 7H)-dione derivatives, in free, salt or prodrug form, are useful as pharmaceuticals, particularly as phosphodiesterase 1 inhibitors, useful treatment of diseases involving disorders of the dopamine D1 receptor intracellular pathway, such as Parkinson's disease, depression, narcolepsy and damage to cognitive function, e.g.,... Agent: Hoxie & Associates LLC

20100273754 - Organic compounds: 1- or 2-substituted (6aR,9aS)-3-(phenylamino)-5-6a,7,8,9,9a-hexahydro-5-methyl-cyclopent[4,5]imidazo[1,2-a]pyrazolo[4,3-e]pyrimidin-4(1H or, 2H)-one compounds of Formula (I), processes for their production, their use as pharmaceuticals and pharmaceutical compositions comprising them.... Agent: Hoxie & Associates LLC

20100273757 - Pyrazine derivatives useful as adenosine receptor antagonists: The present invention provides a compound of formula (I) wherein: A represents an optionally substituted monocyclic or polycyclic aryl or heteroaryl group B represents an optionally substituted monocyclic nitrogen-containing heteroaryl group; and either a) R1 and R2 represent hydrogen or specified substituents, or b) R2, R1 and the —NH— group... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20100273750 - Serotonin receptor antagonists for treating arthritis: The present invention relates to serotonin receptor antagonists for treating inflammatory arthritis and related conditions. The present invention also relates to a kit comprising a pharmaceutical composition comprising a serotonin receptor antagonist and instructions indicating that the composition is for use in treating inflammatory arthritis and related conditions. In addition,... Agent: Karen S. Canady Canady & Lortz LLP

20100273751 - Substituted benzoimidazolyl-pyrazine compounds for inflammation and immune-related uses: This invention relates to certain biologically active chemical compounds, namely benzoimidazolyl-pyrazine derivatives or pharmaceutically acceptable salts, solvates, clathrates, or prodrugs thereof. These compounds are useful as immunosuppressive agents and for treating and preventing inflammatory conditions, allergic disorders, and immune disorders.... Agent: Synta Pharmaceuticals Corp. C/o Wolf, Greenfield & Sacks, P.C.

20100273758 - Sulfonamide derivatives for the treatment of diseases: i

20100273759 - Progesterone antagonists: Described herein are compounds which exhibit progesterone antagonistic effects and methods of treating cancer using such compounds.... Agent: Meyertons, Hood, Kivlin, Kowert & Goetzel, P.C.

20100273760 - Topical pharmaceutical formulations and methods of treatment: In certain embodiments, the present invention is directed to a pharmaceutical formulation for topical administration on a mammal, comprising a unit dose of a therapeutically effective amount of a therapeutic agent and a pharmaceutically acceptable carrier medium therefor, said formulation being solid at ambient temperature and having a softening point... Agent: Davidson, Davidson & Kappel, LLC

20100273761 - Nuclear sulfated oxysterol, potent regulator of lipid homeostasis, for therapy of hypercholesterolemia, hypertriglycerides, fatty liver diseases, and atherosclerosis: The sulfated oxysterol 5-cholesten-3β, 25-diol 3-sulphate, a nuclear cholesterol metabolite that decreases lipid biosynthesis and increases cholesterol secretion and degradation, is provided as an agent to lower intracellular and serum cholesterol and/or triglycerides, and to prevent or treat lipid accumulation-associated inflammation and conditions associated with such inflammation. Methods which involve... Agent: Whitham, Curtis & Christofferson & Cook, P.C.

20100273762 - Method of combating infection: A method of combating a parasitic protozoal infection of a host organism, the method comprising administering tretazicar to the host organism. Tretazicar is the compound 5-(aziridin-1-yl)-2,4-dinitrobenzamide (CB 1954), and the parasitic infection is preferably an infection of Trypanosoma cruzi, T. b. brucei, Leishmania spp. particularly L. infantum, Cryptosporidium or Giardia... Agent: Nixon & Vanderhye, PC

20100273763 - Organometallic complexes as therapeutic agents: This invention comprises salophene-based metallic complexes. Included are metal-chelating analogues, and method of their preparation and use. These analogues have therapeutic activity including anticancer activity.... Agent: Rissman Hendricks & Oliverio, LLP

20100273764 - Inhibitors of pi3 kinase and/or mtor: i

20100273765 - Rifamycin analogs and uses thereof: The present invention features rifamycin analogs that can be used as therapeutics for treating or preventing a variety of microbial infections. In one form, the analogs are acetylated at the 25-position, as is rifamycin. In another form, the analogs are deacetylated at the 25-position. In yet other forms, benzoxazinorifamycin, benzthiazinorifamycin,... Agent: Intellectual Property / Technology Law

20100273766 - Substituted oxindol derivatives, medicaments containing said derivatives and use thereof: The invention relates to novel oxindole derivatives of general formula (I), wherein the substituents R1, R2, A, B, and Y are defined as in claim 1. The invention further relates to medicaments containing said derivatives, and use thereof for the prevention and/or treatment of vasopressin-dependent diseases.... Agent: Dykema Gossett PLLC

20100273768 - Inhibitors of bruton's tyrosine kinase: wherein, variables Q1, Q2, R, X, Y1, Y2, Y2′, Y3, Y4, Y5, m, and p are defined as described herein, which inhibit Btk. The compounds disclosed herein are useful to modulate the activity of Btk and treat diseases associated with excessive Btk activity. The compounds are further useful to treat... Agent: Hoffmann-la Roche Inc. Patent Law Department

20100273769 - Composition and method for the treatment of parkinson's disease: The present invention relates to the use of specific indolocarbazole compounds for the preparation of pharmaceutical compositions for the treatment of Parkinson's disease. In particular, the compounds of the invention are useful for the prevention or treatment of PD, similar forms of Parkinsonism, and synucleopathies involving Lewy body neurodegeneration.... Agent: Lahive & Cockfield, LLP Floor 30, Suite 3000

20100273770 - 1, 2, 4 -oxadiazole compounds for the treatment of autoimmune diseases: The present invention relates to novel oxadiazole derivatives having pharmacological activity, processes for their preparation, pharmaceutical compositions containing them and their use in the treatment of various disorders.... Agent: Glaxosmithkline Global Patents -us, Uw2220

20100273772 - Bisaryl alkynylamides as negative allosteric modulators of metabotropic glutamate receptor 5 (mglur5): e

20100273771 - Oxadiazole derivatives active on sphingosine-1-phosphate (sip): The present invention relates to novel oxadiazole derivatives having pharmacological activity, processes for their preparation, pharmaceutical compositions containing them and their use in the treatment of various disorders.... Agent: Glaxosmithkline Global Patents -us, Uw2220

20100273767 - Modulators of 5-ht receptors and methods of use thereof: e

20100273773 - Dibenzoazepine and dibenzooxazepine trpa1 agonists: The present invention is related to novel tricyclic compounds of formula (I) having TRPA1 receptor agonistic properties, pharmaceutical compositions comprising these compounds, chemical processes for preparing these compounds and their use as pharmacological tools, or as irritant incapacitants, or in the treatment of diseases linked to the modulation of the... Agent: Philip S. Johnson Johnson & Johnson

20100273774 - Indolymaleimide derivatives: A compound of formula (I), wherein R, R1, R2, ring A, which ring contains one or two nitrogen atoms, and ring B are as defined in the Specification, pharmaceutical compositions containing these compounds, and uses for these compounds and compositions, in particular, in transplantation.... Agent: Hoxie & Associates LLC

20100273775 - Fungicidal bicyclic pyrazoles: Also disclosed are compositions containing the compounds of Formula 1 and methods for controlling plant disease caused by a fungal pathogen comprising applying an effective amount of a compound or a composition of the invention. Further disclosed is a method for preparing compounds of Formula 1 from compounds of Formula... Agent: E I Du Pont De Nemours And Company Legal Patent Records Center

20100273776 - Inhibition of alpha-synuclein toxicity: Compounds and compositions are provided for treatment or amelioration of one or more symptoms of α-synuclein toxicity, α-synuclein mediated diseases or diseases in which α-synuclein fibrils are a symptom or cause of the disease.... Agent: Fish & Richardson P.C.

20100273777 - Compounds for modulating trpv3 function: The present application relates to compounds and methods for treating pain and other conditions related to TRPV3.... Agent: Foley Hoag, LLP Patent Group, World Trade Center West

20100273778 - Treatment of osteoarthritis pain: This invention discloses a method of treatment of osteoarthritis pain by administration of a histamine H3 receptor antagonist, described herein, a salt thereof, or a composition comprising such compound or salt.... Agent: Paul D. Yasger Abbott Laboratories

20100273779 - Pyridazinone derivatives: The present invention is directed to novel pyridizinone derivatives that mediate enzymatic activity. In particular, the compounds may be effective in the treatment of diseases or disease states related to the activity of the histamine H3 receptor, including, for example, neurodegenerative disorders, sleep/wake disorders, attention deficit hyperactivity disorder and cognition.... Agent: Ross J. Oehler Cephalon, Inc.

20100273782 - 2,5-disubstituted arylsulfonamide ccr3 antagonists: Provided herein are 2,5-disubstituted arylsulfonamides that are useful for modulating CCR3 activity, and pharmaceutical compositions thereof. Also provided herein are methods of their use for treating, preventing, or ameliorating one or more symptoms of a CCR3-mediated disorder, disease, or condition.... Agent: Jones Day

20100273781 - Cxcr3 receptor antagonists: and pharmaceutically acceptable salts thereof, wherein R1 to R6, A, B, X, Y and n are as defined herein. The invention also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful... Agent: Michael P. Morris Boehringer Ingelheim Usa Corporation

20100273780 - Substituted 8-heteroaryl xanthines: The present invention provides compounds and pharmaceutical compositions that are selective antagonists of A2B adenosine receptors (ARs). These compounds and compositions are useful as pharmaceutical agents.... Agent: Clinical Data, Inc. Attn: Amy Medel

20100273783 - Compositions and methods for treating and preventing overactive bladder and conditions associated therewith: Compositions and methods for the treatment and prevention of overactive bladder are provided. Such compositions and methods provide locally effective amounts of diazepam sufficient to treat or prevent overactive bladder and conditions associated therewith.... Agent: Lucas & Mercanti, LLP

20100273784 - Fused ring heterocycles as potassium channel modulators: Compounds, compositions and methods are provided which are useful in the treatment of diseases through the modulation of potassium ion flux through voltage-dependent potassium channels. More particularly, the invention provides quinazolinone, compositions and methods that are useful in the treatment of central or peripheral nervous system disorders (e.g., migraine, ataxia,... Agent: Townsend And Townsend And Crew, LLP

20100273785 - 2,5-disubstituted arylsulfonamide ccr3 antagonists: m

20100273786 - Tetrahydro-imidaz0[1,5-a]pyrazine derivatives, preparation process and medicinal use thereof: Tetrahydro-imidazo[1,5-a]pyrazine derivatives of formula (I), their preparation methods, pharmaceutical compositions containing the derivatives and uses thereof as medicaments, especially as dipeptidyl peptidase IV inhibitors, wherein the substituents of formula (I) are defined as same as the description.... Agent: Brinks Hofer Gilson & Lione

20100273787 - Kynurenine-aminotransferase inhibitors: Compounds of formula (I): prodrug derivatives and/or pharmaceutically acceptable salt thereof, selectively inhibit the enzyme kynurenine aminotransferase, thereby reducing the synthesis of kynurenic acid. The compounds are used for the treatment of psychiatric and neurological diseases which benefit from an increase in glutamatergic and/or cholinergic neurotransmission, such as schizophrenia, depression,... Agent: Whitham, Curtis & Christofferson & Cook, P.C.

20100273788 - Fused heterocyclic derivative and use thereof: wherein each symbol is as defined in the specification, except a particular compound, or a salt thereof, and a pharmaceutical agent containing the compound or a prodrug thereof, which is a kinase (VEGFR, VEGFR2, PDGFR, Raf) inhibitor, an angiogenesis inhibitor, an agent for the prophylaxis or treatment of cancer, a... Agent: Hamre, Schumann, Mueller & Larson, P.C.

20100273789 - Aminoacyl prodrugs: The present application relates to prodrug derivatives of 5-chloro-N-({(5S)-2-oxo-3-[2-fluoro-4-(3-oxomorpholin-4-yl)phenyl]-1,3-oxazolidin-5-yl}methyl)thiophene-2-carboxamide, processes for their preparation, their use for the treatment and/or prophylaxis of diseases, and their use for the manufacture of medicaments for the treatment and/or prophylaxis of diseases, especially of thromboembolic disorders.... Agent: Barbara A. Shimei Director, Patents & Licensing

20100273790 - Processes for the preparation of rivaroxaban and intermediates thereof: e

20100273791 - Tricyclic pyrazole derivatives as cannabinoid receptor modulators:

20100273792 - Macrocyclic indoles as hepatitis c virus inhibitors:

20100273793 - 6-aryl/heteroalkyloxy benzothiazole and benzimidazole derivatives, method for preparing same, application thereof as drugs, pharmaceutical compositions and novel use in particular as c-met inhibitors:

20100273794 - Benzimidazolone compounds having 5-ht4 receptor agonistic activity:

20100273795 - Arylsulfonamide ccr3 antagonists: Provided herein are arylsulfonamides that are useful for modulating CCR3 activity, and pharmaceutical compositions thereof. Also provided herein are methods of their use for treating, preventing, or ameliorating one or more symptoms of a CCR3-mediated disorder, disease, or condition.... Agent: Jones Day

20100273796 - 2-benzylpyridazinone derivatives as met kinase inhibitors: o

20100273797 - Alpha-ketoamides and derivatives thereof: The present invention provides low molecular weight compounds useful as cytokine inhibitors, and compositions thereof. In particular, compounds of the invention are useful as anti-inflammatory agents. There are further provided methods for the preparation of such agents and their use in preventing or treating conditions medicated by cytokines such as... Agent: Foley & Lardner LLP

20100273798 - Processes for the preparation of rivaroxaban and intermediates thereof: e

20100273799 - Small molecule inhibitors of mdm2 and the uses thereof: The invention relates to small molecules which function as inhibitors of the interaction between p53 and MDM2. The invention also relates to the use of these compounds for inhibiting cell growth, inducing cell death, inducing cell cycle arrest and/or sensitizing cells to additional agent(s).... Agent: Casimir Jones, S.c.

20100273800 - Pyrrolotriazine derivatives useful for treating cancer through inhibition of aurora kinase: This invention relates to novel compounds and processes for their preparation, methods of treating diseases, particularly Cancer, comprising administering said compounds, and methods of making pharmaceutical compositions for the treatment or prevention of disorders, particularly Cancer.... Agent: Edwards Angell Palmer & Dodge LLP

20100273801 - Betulin derived compounds useful as antibacterial agents: The invention relates to compouns derived from betulin, and to the use thereof as antibacterial agents in pharmaceutical and cosmetic applications.... Agent: Birch Stewart Kolasch & Birch

20100273802 - New purine derivatives having, in particular, anti-proliferative properties, and their biological uses: This invention provides 2-, 6, and 9-substituted purine derivatives, particularly 2(1-R hydroxymethylpropylamino)-6-benzylamino-9-isopropyl purine, having, in particular, antiproliferative properties, and suitable for use as pharmaceutical compositions and herbicidal compositions. Also provided are pharmaceutical compositions and herbicidal compositions comprising the 2-, 6, and 9-substituted purine derivatives, and methods of treatment using the... Agent: Foley And Lardner LLP Suite 500

20100273803 - Oral formulations for tetrapyrrole derivatives: Oral formulations and method of formulating photosensitive agents for oral administration during photodynamic therapy (PDT) and Antimicrobial photodynamic therapy (APDT) treatment are presented. The oral formulated photosensitizers show increased solubility and permeability, thus improving the bioavailability of photosensitizers at the treatment site. An orally administered photosensitizer is suitably formulated for... Agent: Bolesh J. Skutnik Ceramoptec Industries, Inc.

20100273804 - Pyridazine derivatives useful as fungicides and for the treatment of cancer: The present invention relates to novel pyridazine derivatives of formula (I) as active ingredients which have microbiocidal activity, in particular fungicidal activity: formula (I) wherein R1 is C1-C6alkyl, C1-C6haloalkyl or C3-C6cycloalkyl; R2 is hydrogen or an optionally substituted alkyl, aryl or heteroaryl; R3 is hydrogen, C1-C6alkyl or C1-C6haloalkyl; R4 is... Agent: Syngenta Crop Protection , Inc. Patent And Trademark Department

20100273805 - Sulphide bridged derivatives as modulators of mglur5 733: The present invention is directed to novel compounds, to a process for their preparation, their use in therapy and pharmaceutical compositions comprising the novel compounds.... Agent: Birch, Stewart, Kolasch & Birch, LLP

20100273806 - Tetrahydrocyclopenta[b]indol-3-yl carboxylic acid derivatives useful in the treatment of autoimmune and inflammatory disorders: The present invention relates to certain (1,2,4-oxadiazol-3-yl)-1,2,3,4-tetrahydrocyclo-penta[b]indol-3-yl carboxylic acid derivatives of Formula (Ia) and pharmaceutically acceptable salts thereof, which exhibit useful pharmacological properties, for example, as agonists of the S1P1 receptor. Also provided by the present invention are pharmaceutical compositions containing compounds of the invention, and methods of using the... Agent: Fish & Richardson PC

20100273807 - Use of pde iii inhibitors for the treatment of asymptomatic (occult) heart failure: The invention relates to the use of a phosphodiesterase type III (PDE III) inhibitor or Ca2+-sensitizing agent or a pharmaceutically acceptable derivative thereof for the preparation of a medication for the prolongation of time until onset of clinical symptoms in patents having an asymptomatic (occult) heart failure or for the... Agent: Michael P. Morris Boehringer Ingelheim Usa Corporation

20100273808 - Lactate salt of 4-[6-methoxy-7-(3-piperidin-1-yl-propoxy)quinazolin-4-yl]piperazine-1-carboxylic acid(4-isopropoxyphenyl)-amide and pharmaceutical compositions thereof for the treatment of cancer and other diseases or disorders: or a crystalline form thereof, or a pharmaceutical composition thereof, or an oral pharmaceutical dosage form thereof; processes for the synthesis or manufacture of the compound of formula (I), or a crystalline form thereof, or a pharmaceutical composition thereof, or an oral pharmaceutical dosage form thereof; and the use of... Agent: Millennium Pharmaceuticals, Inc.

20100273809 - Method and composition for treating an alpha adrenoceptor-mediated condition: Methods and compositions for the treatment of alpha-adrenoceptor mediated conditions.... Agent: Hoffman Warnick LLC

20100273810 - Method of treating cognitive impairments and schizophrenias: t

20100273811 - N-[5-[2-(3,5-dimethoxyphenyl)ethyl]-1h-pyrazol-3-yl]-4-(3,4-dimethylpiperazin-1-yl)benzamide and salts thereof:

20100273812 - Diazo bicyclic smac mimetics and the uses thereof: The invention relates to diazo bicyclic mimetics of Smac which function as inhibitors of Inhibitor of Apoptosis Proteins. The invention also relates to the use of these mimetics for inducing apoptotic cell death and for sensitizing cells to inducers of apoptosis.... Agent: Casimir Jones, S.c.

20100273813 - Novel n-phenylacetamide inhibitors of the enzyme soat-1 and pharmaceutical/cosmetic compositions comprised thereof: e

20100273814 - ((phenyl)imidazolyl)methylheteroaryl compounds: Disclosed herein is a compound of the formula wherein A and B are described herein. Therapeutic methods, compositions, and medicaments related thereto are also disclosed.... Agent: Allergan, Inc.

20100273815 - Thieno[2,3-d]-pyrimidin-4(3h)-one compounds with antifungal properties and process thereof: The present invention discloses novel compounds of the Formula (1), containing thieno-[2,3-d]pyrimidin-4(3H)-one moieties and pharmaceutically acceptable salts thereof, methods for preparing these compounds, the use of these compounds in prevention and treatment of fungal infections, and pharmaceutical preparations containing these novel compounds.... Agent: Kramer & Amado, P.C.

20100273816 - Quinazoline compounds: in which R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, R12, R13, R14, R15, W, W1, W2, W3, A, Ra, Ra′, Rb, Rb′, Rc, Rd, Rd′, Re, Rf, Rg, Rh, Ri Rj, Rk, Rm, Rn, Ro, Rp, Rq, and n, can be, independently, as defined anywhere herein.... Agent: Wyeth LLC Patent Law Group

20100273817 - Anti-cancer cyclopenta(g)quinazoline compounds: Cyclopenta[g]quinazolines of the formula (I):—wherein: A is a group OR or NR0R1 wherein R0 and R1 are each independently hydrogen C1-4 alkyl, C3-4 alkenyl, C3-4 alkynyl, C2-4 hydroxyalkyl, C2-4 halogenoalkyl or C1-4 cyanoalkyl, or R0 and R1 together with the intermediate N form a five- or six-membered heterocyclic ring; p... Agent: Nixon & Vanderhye, PC

20100273819 - 3,3'-spiroindolinone derivatives: c

20100273818 - Inhibitors of hedgehog signaling pathways, compositions and uses related thereto: The present invention makes availables assays and reagents inhibiting paracrine and/or autocrine signals produced by a hedgehog protein or aberrant activation of a hedgehog signal transduction pathway, e.g., which involve the use of a steroidal alkaloid or other small molecule.... Agent: Ropes & Gray LLP

20100273820 - Peripheral phenolic opioid antagonist: N-Methyldiprenorphine, useful as an opioid antagonist.... Agent: Pharmacofore, Inc. Bozicevic, Field & Francis LLP

20100273822 - Immediate release compositions and methods for delivering drug formulations using strong acid ion exchange resins: Solid oral dosage immediate release compositions comprising strong acid ion exchange resins and methods for delivering drug formulations.... Agent: Sheldon Kavesh, Ph. D.

20100273821 - Methods and compositions for treating dry eye: This invention relates to treatment of dry eye. In particular, the invention relates to methods and formulations for treating dry eye based on topical application of opioid antagonists such as naltrexone.... Agent: Scully Scott Murphy & Presser, PC

20100273823 - Pesticide composition solution and preparation method thereof: Wherein: R1 is Na or K, and R2 is H or OH. The pesticide composition solution in this invention can be processed using simple methods, does not require the use of organic solvents, can reduce environmental pollution, and will greatly lower pesticide production costs. In addition to the good pest... Agent: GlobalIPServices

20100273824 - Substituted 1,3-dioxanes and their uses: The present invention relates to compounds containing 1,3-dioxane moiety, pharmaceutical compositions thereof, and the use of the compounds and compositions for the modulation of thromboxane A2 or a peroxisome proliferator-activated receptor. The compounds, analogs, and pharmaceutically acceptable salts thereof, and pharmaceutical compositions can be used in the treatment and prevention... Agent: Mcdonnell Boehnen Hulbert & Berghoff LLP

20100273825 - Solid pharmaceutical composition containing solifenacin amorphous form: The present invention relates to the provision of a stable solid pharmaceutical composition containing an amorphous form of solifenacin or a pharmaceutically acceptable salt thereof and capable of inhibiting decomposition accompanied by long-term storage, to provide the medical field with a formulation of solifenacin or a pharmaceutically acceptable salt thereof.... Agent: Sughrue Mion, PLLC

20100273826 - Methods of use and compositions for the diagnosis and treatment of infectious diseases: Methods and compositions for treating disease caused by infectious agents, particularly tuberculosis. In particular, methods and compositions comprising substituted diamines for the treatment of infectious diseases are provided. In one embodiment, these methods and compositions are used for the treatment of mycobacterial infections, including, but not limited to, tuberculosis.... Agent: King & Spalding

20100273827 - Oxadiazole derivatives active on sphingosine-1-phosphate (s1p): The present invention relates to novel oxadiazole derivatives having pharmacological activity, processes for their preparation, pharmaceutical compositions containing them and their use in the treatment of various disorders.... Agent: Glaxosmithkline Global Patents -us, Uw2220

20100273828 - 4-(4-pyridinyl)-benzamides and their use as rock activity modulators: The present invention relates to novel 4-(4-pyridyl)-benzamides of the formula (I). The compounds I possess valuable therapeutic properties and are suitable, in particular, for treating diseases that respond to modulation of Rho kinases (ROCKs). R1 and R2 are, independently of each other, hydrogen, hydroxy, cyano, C1-C8-alkyl, C1-C8-haloalkyl, C1-C8-alkoxy or C1-C8-haloalkoxy;... Agent: Abbott Laboratories C/o Polsinelli Shughart PC

20100273829 - Methods for treating disorders associated with hyperlipidemia in a mammal: The invention is directed to methods for treating disorders associated with hyperlipidemia in a mammal. The methods involve combination therapies using a microsomal triglyceride transfer protein (MTP) inhibitor (for example, BMS-201038 and implitapide) and a fibrate (for example, fenofibrate). Co-administration of the MTP inhibitor with the fibrate produces a therapeutic... Agent: Goodwin Procter LLP Patent Administrator

20100273831 - Fluoro alkyl substituted benzimidazole cannabinoid agonists: The present invention is related to novel benzimidazole compounds of formula (I) having cannabinoid receptor agonistic properties, pharmaceutical compositions comprising these compounds, chemical processes for preparing these compounds and their use in the treatment of diseases linked to the mediation of the cannabinoid receptors in animals, in particular humans.... Agent: Philip S. Johnson Johnson & Johnson

20100273830 - Novel insecticides: An insecticidal compound of formula (I) in which G1, G2, and G3 together with the two carbon atoms to which G1 and G3 are attached, form a non-aromatic 4- or 5-membered ring system; wherein G1 is sulfur, SO, SO2, oxygen, a direct bond, NRa or CR5aR5b; G2 is sulfur, SO,... Agent: Syngenta Crop Protection , Inc. Patent And Trademark Department

20100273832 - Insecticidal compounds: A compound of formula (I): wherein A1, A2, A3, A4, G1, R1, R2, R3 and R4 are as defined in claim 1; or a salt or N-oxide thereof. Furthermore, the present invention relates to processes and intermediates for preparing compounds of Formula (I), to insecticidal, acaricidal, molluscicidal or nematicidal compositions... Agent: Syngenta Crop Protection , Inc. Patent And Trademark Department

20100273833 - 2-sulfinyl- and 2-sulfonyl-substituted imidazole derivatives and their use as cytokine inhibitors: The invention relates to 2-sulfinyl- or 2-sulfonyl-substituted imidazole derivatives of the formula (I) in which the radicals R1, R2, R3 and R4 have the meaning indicated in the description. The compounds of the invention have an immunomodulating and/or cytokine release-inhibiting effect and are therefore suitable for the treatment of disorders... Agent: Viksnins Harris & Padys Pllp

20100273834 - Treatment of onychomycosis and related compositions including urea: The present invention generally relates to the treatment of onychomycosis. More specifically, it relates to combination therapies for the treatment of onychomycosis and related compositions. In a composition aspect, the present invention provides a composition for the treatment of onychomycosis, wherein the composition includes Ciclopirox and urea. In a method... Agent: Karen S. Canady Canady & Lortz LLP

20100273835 - Novel compounds: e

20100273836 - Oxime ether derivative and fungicide for agricultural and horticultural use: The present invention provides a novel oxime ether derivative represented by the following formula (I), or salt thereof, that can be industrially produced advantageously, and can function as a fungicide for agricultural and horticultural use that has reliable effects and can be used safely, and a fungicide for agricultural and... Agent: Kenyon & Kenyon LLP

20100273837 - Antibacterial agents: Compounds of formula (IA) or (IB) have antibacterial activity: wherein W is ═CH— or ═N—; Ri and R2 are independently selected from hydrogen, fluoro and chloro, provided that Ri and R2 are not each hydrogen when W is ═CH—; n is 0 or 1; X is —O—, —S—, or —CH2—;... Agent: Banner & Witcoff, Ltd.

20100273838 - Stable topical compositions for 1,2,4-thiadiazole derivatives: The present application provides a stable topical composition comprising a compound of 1,2,4-thiadiazole derivatives and the related thiourea derivatives. The stable topical composition may be present in various forms, including aqueous gel, cream, and emulsion. The stable topical composition may be stored at refrigerated or ambient condition for a reasonable... Agent: Philip S. Johnson Johnson & Johnson

20100273839 - Compounds having activity in correcting mutant-cftr processing and uses thereof: The invention provides compositions, pharmaceutical preparations and methods for increasing activity of a mutant cystic fibrosis transmembrane conductance regulator protein (mutant-CFTR). The compositions pharmaceutical preparations and methods are useful for the study and treatment of disorders associated with mutant-CFTR, such as cystic fibrosis. The compositions and pharmaceutical preparations of the... Agent: Bozicevic, Field & Francis LLP

20100273842 - Amine derivatives having npy y5 receptor antagonistic activity and the uses thereof: e

20100273841 - Amine-derivatives having npy y5 receptor antagonistic activity and the uses thereof:

20100273840 - Water-soluble polymer-based cantharimides as potentially selective anti-tumor agents: A cantharimide compound may include the backbone of formula (1). R1, R2, R3, and R4 may be independently selected from the group consisting of H, C(O)OR5, C(O)R6, C(O)NR7R8, NR9C(O)R10, N—R11R12, O—R13, S—R14, P(O)(OR15)(OR16), As(O)(OR17)(OR18), SO2R19, SO3R20, and B(OR21). X1 to X4 may be independently selected from the group consisting of... Agent: Wilkinson & Grist

20100273843 - Heterocyclic self-immolative linkers and conjugates: The present invention provides heterocyclic linker compounds useful for linking drug moieties to ligands. The compounds also include drug-ligand conjugates comprising a ligand capable of targeting a selected cell population, and a drug connected to the ligand by a heterocyclic linker moiety. The linker moiety comprises a peptide sequence that... Agent: Seattle Genetics, Inc.

20100273844 - Pharmaceutical compositions for treating or preventing migaines: The present invention provides a method for treating or preventing one or more types of migraines by administering a monoamine oxidase inhibitor, preferably isocarboxazid, in a rapid-release formulation. The present invention also provides a pharmaceutical composition suitable for treating or preventing migraines and having at least one monoamine oxidase inhibitor.... Agent: Leslie G Restaino Validus Pharmaceuticals Inc

20100273845 - Angiotensin ii receptor antagonists: e

20100273846 - Method for treating proliferative disorders associated with mutations in c-met: The present invention relates to methods of inhibiting the activity of Hsp90 in a subject in need thereof and methods for treating c-Met associated cancers, in a subject in need thereof.... Agent: Foley & Lardner LLP

20100273847 - Desferrioxamine conjugates, derivatives and analogues: The present invention relates to desferoxamine conjugates, derivatives and analogues thereof. In particular, the present invention relates to desferoxamine conjugates, analogues and derivatives thereof, and methods for reducing levels of metals, especially iron, in a mammal. Uses of the compounds according to the invention are also provided. Compounds of the... Agent: Marshall, Gerstein & Borun LLP

20100273848 - Iminopyrrolidone thiol amino acid conjugates, pharmaceutical compositions and methods for the treatment of cancer: Compounds, compositions and methods for the treatment of cancer are disclosed herein. Embodiments of the present invention include compounds having the formula: (I), wherein R1 is selected from hydrogen or substituted or unsubstituted (C1-C6) alkyl or (C3-C6) cycloalkyl, R2 and R3 are independently selected from hydrogen, substituted or unsubstituted (C1-C6)... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, L.L.P.

20100273849 - Metalloproteinase inhibitors: m

20100273850 - 4-heteroaryl-substituted phenoxyphenylacetic acid derivatives: Compounds of Formula I: I in which D1, D2, R1, R2, R7, R8 and A have the meanings given in the specification, are DP2 receptor modulators useful in the treatment of immunologic diseases.... Agent: Viksnins Harris & Padys Pllp

20100273851 - Methods of using proteinacious channels to identify pharmaceutical treatments and risks, and treatments resulting therefrom: Methods and therapeutic strategies utilizing proteinacious channels in lipid membranes of mammalian cells. The methods entail administering a pharmaceutical to a lipid membrane of a mammalian cell, and then determining the effect of the pharmaceutical on the electrophysiology of at least one proteinacious channel of the lipid membrane, wherein the... Agent: Hartman & Hartman, P.C.

20100273852 - Pharmaceutical composition: There is provided a pharmaceutical composition comprising (1) (R)-5,6-dimethoxy-2-[2,2,4,6,7-pentamethyl-3-(4-methylphenyl)-2,3-dihydro-1-benzofuran-5-yl]isoindoline, (2) a lipophilic component, and (3) a surfactant, which can stably and sufficiently provide improvement in the absorbability of the drug without being affected by the amount and quality of a meal.... Agent: Edwards Angell Palmer & Dodge LLP

20100273853 - Novel isoindol derivatives as ep4 receptor agonists: e

20100273868 - R-zileuton for use in conditions associated with increased 5-lipoxygenase and/or leukotriene activity (eg asthma): The invention pertains to a method of treating a condition mediated by or characterized by increased 5-lipoxygenase activity like for instance asthma in a patient suffering therefrom comprising administering to said patient a composition comprising (R)-zileuton and a pharmaceutically acceptable excipient, wherein said composition is substantially free of (S)-zileuton.... Agent: Foley & Lardner LLP

20100273869 - Anti-cancer tocotrienol analogues and associated methods: Compounds are disclosed relating to the treatment of cancer that include tocotrienols and derivatives of tocotrienols including 2,5,7,8-tetramethyl-2-((3E,7E)-4,8,12-trimethyltrideca-3,7,11-trienyl)chroman-6-ylphenylsulfonylcarbamate; (R)-2,8-dimethyl-2-((3E,7E)-4,8,12-trimethyltrideca-3,7,11-trienyl)chroman-6-yl tosylcarbamate; and (R)-2,5,7,8-tetramethyl-2-((3E,7E)-4,8,12-trimethyltrideca-3,7,11-trienyl)chroman-6-yl benzylcarbamate. Therapeutic uses of these types of compounds are also taught.... Agent: Kean, Miller, Hawthorne, D'armond, Mccowan & Jarman, L.L.P.

20100273870 - Compositions and methods for treating demodex infestations: Compositions containing about 0.6% to about 20% of tea tree oil are described. Some compositions are in the form of solutions, suspensions, spray, lotions, gels, pastes, medicated sticks, balms, cleansers (including shampoos and soaps), creams, or ointments. Also described are compositions and methods for use in treating ocular Demodex infestations... Agent: Wilson, Sonsini, Goodrich & Rosati

20100273871 - Anticancer tocopheryl succinate derivatives: wherein X is selected from oxygen, nitrogen and sulfur; n is 0 or 1; R1 is selected from alkyl, carboxylic acid, carboxylate, carboxamide, ester and combinations thereof; R2 is selected from alkyl, substituted alkyl, carboxylic acid, carboxylate, carboxamide, sulfonyl, sulfonamide and combinations thereof; and derivatives and metabolites thereof. Further provided... Agent: Calfee Halter & Griswold, LLP

20100273872 - Use of 4-oxobutanoic acid derivatives in the treatment of pathologies associated with immunological disorders: The present invention relates to the use of a 4-oxobutanoic acid derivative for the preparation of a pharmaceutical composition for the treatment of pathologies associated with immunological disorders.... Agent: Millen, White, Zelano & Branigan, P.C.

20100273873 - Direct compressible dextrose: This invention relates to a direct compressible dextrose composition, a process for preparing such a direct compressible dextrose composition by compression and subsequent granulation, and processes for preparing pharmaceutical formulations or food formulations in tablet form using the direct compressible dextrose composition. The invention further concerns pharmaceutical or food formulations,... Agent: Cargill, Incorporated

20100273874 - Use of propineb as bird repellent: The present invention relates to the novel use of Propineb as bird repellent.... Agent: Baker Donelson Bearman, Caldwell & Berkowitz, PC

20100273875 - Composition for external application to skin: wherein R1 is a substituted or unsubstituted, linear or branched chain alkyl group having 2 to 25 carbon atoms; X is —CO—NH—, —O—CO—O—, —NH—CO—, —CO—O—, —O—CO— or —O—; Y is a substituted or unsubstituted alkylene group having 1 to 4 carbon atoms; R2 is a hydrogen atom or an alkyl... Agent: Sterne, Kessler, Goldstein & Fox P.l.l.c.

20100273876 - antibacterial formulation comprising a dialkyl sulphosuccinate and a carbanilide antibacterial agent: Antibacterial formulation containing (a) a dialkyl sulphosuccinate (DAS) or derivative thereof and (b) a carbanilide antibacterial agent such as triclocarban (TCC). The formulation may be for use in the treatment of a bacterial condition, in particular acne, body odour or a condition affecting the oral cavity. It may contain, in... Agent: Weaver Austin Villeneuve & Sampson LLP

20100273877 - Emulsified skin external preparations and cosmetics: t

20100273878 - Preventive or therapeutic drug for alzheimer-type dementia: It is intended to provide a highly safe preventive or therapeutic drug for Alzheimer-type dementia which can replace the conventional therapies currently used for Alzheimer-type dementia or which can be used together with the conventional therapy to realize high therapeutic effects, characterized in that a ω-3 polyunsaturated fatty acid and... Agent: Birch Stewart Kolasch & Birch

20100273879 - Method for producing acylglycinates: wherein R1 represents a linear or branched, saturated alkanoyl group having between 6 and 30 carbon atoms, or a linear or branched, mono- or polyunsaturated alkenoyl group having between 6 and 30 carbon atoms, and Q+ represents a cation selected from the alkali metals Li+, Na+ and K+, characterised in... Agent: Clariant Corporation Intellectual Property Department

20100273880 - Storage-stable aqueous composition comprising a magnesium compound and l-carnitine: The present invention relates to a storage-stable aqueous or gel-like composition or solution comprising a magnesium compound selected from a magnesium salt or a magnesium complex compound, and L-carnitine, and the use thereof for the preparation of a medicament for supporting metabolism, in particular in muscle tissue, and for supporting... Agent: Renner Otto Boisselle & Sklar, LLP

20100273881 - Lipid compositions for the treatment of gastro-intestinal disorders and the promotion of intestinal development and maturation: The present invention provides a use of a lipid composition for the preparation of a nutritional, pharmaceutical or nutraceutical composition or a functional food, for the prevention and treatment of gastrointestinal diseases and disorders, and for promoting intestinal development, maturation, adaptation and differentiation.... Agent: Greenberg Traurig, LLP

20100273882 - Method for the treatment of acne using compositions comprising 0.3% by weight of 6-[3-(1-adamantyl)-4-methoxyphenyl]-2-naphthoic acid: Dermatological disorders having an inflammatory or proliferative component, notably common acne, are treated with topically applicable pharmaceutical compositions containing about 0.3% by weight of 6-[3-(1-adamantyl)-4-methoxyphenyl]-2-naphthanoic acid (adapalene) or salt thereof, formulated into pharmaceutically acceptable media therefor, advantageously formulated into topically applicable gels, preferably aqueous gels, creams, lotions or solutions.... Agent: Buchanan, Ingersoll & Rooney PC

20100273883 - Novel ligand activators of the rar receptors and pharmaceutical/cosmetic applications thereof: r

20100273885 - Low environmental impact pesticide made from \"gras\" ingredients for use against coqui frogs and other species: The current invention involves compositions and methods for killing various soft-bodied animals of interest (more specifically, Coqui frogs and Coqui frog eggs are targeted) with a low pH adjusted pesticide. The method involves contacting the soft-bodied animal of interest with the low pH adjusted pesticide, wherein the pesticide is a... Agent: Ac Innovations LLC/craig C. Conrad

20100273884 - Method for stable and controlled delivery of (-)-hydroxycitric acid: The present invention provides stable encapsulated (−)-hydroxycitric acid (“HCA”)-containing compositions and methods of making the same. A method is provided by which the hygroscopic salts of HCA in their relatively pure and active forms, including especially the potassium salt, but also including the sodium salt, are rendered non-hygroscopic and stable... Agent: Foley & Lardner LLP

20100273886 - Formulations and methods for lyophilization and lyophilates provided thereby: The present invention provides compositions, methods for lyophilizing compounds and making pharmaceutical compositions, and kits providing solutions and lyophilized formulations of compounds. The compositions, methods, and kits are particularly useful in pharmaceutical applications involving therapeutic agents that have low solubility at low pH and medium pH values. Certain embodiments provide... Agent: Arnold & Porter LLP Attn:IPDocketing Dept.

20100273887 - Mixtures comprising pellitorin and uses thereof: The present invention relates to products and mixtures comprising (a) pellitorin and (b) selected cooling agents. The present invention further relates to products and medicaments for soothing irritated oral and/or nasal tissues. The present invention also relates to the use of such mixtures for soothing irritated oral and/or nasal tissues... Agent: Connolly Bove Lodge & Hutz LLP

20100273888 - Polyquaternium-1 synthesis methods and associated formulations: A multipurpose solution for contact lens care, comprising: an aqueous liquid medium; a quaternary ammonium polymer having an average molecular weight as determined by the proton NMR method of at least 28 k, and methods for making the same.... Agent: Abbott Medical Optics, Inc.

20100273889 - Use of a beta blocker for the manufacture of a medicament for the treatment of hemangiomas: The present invention relates the use of a beta blocker for the manufacture of a medicament for the treatment of hemangiomas, for example of infantile hemangiomas. The beta blocker may be a non-selective beta-blocker, for example propranolol. The present invention provides an alternative to the known compounds, e.g. corticosteroids, interferon... Agent: Harness, Dickey & Pierce, P.L.C

20100273890 - Identification of bacterial autoinducer and use in treating bacterial pathogenicity: A bacterial autoinducer, CAI-1, was purified and its structure identified. Methods for synthesis of the autoinducer and its analogues were elucidated. Methods of using the autoinducer or its analogues for treating bacterial pathogenicity and bio film formation are described. Methods for prevention and treatment of cholera are described. Synthetic (S)-3-hydroxytridecan-4-one... Agent: Mathews, Shepherd, Mckay, & Bruneau, P.A.

20100273891 - Isoflavone metabolites: There are disclosed compounds of formulae (I) or (II) in which A is selected from the group consisting of (1), (2), (3) and (4); OH, and one of R1 and R2 is selected from H, OH and OCH3, and the other of R1 and R2 is selected from OH and... Agent: Barnes & Thornburg LLP

20100273892 - Formulations of tocotrienol quinones for the treatment of ophthalmic diseases: A formulation, comprising an ophthalmically effective amount of one or more tocotrienol quinones, particularly of alpha-tocotrienol quinone is disclosed. Use of a formulation comprising one or more tocotrienol quinones for the prevention, reduction, amelioration or treatment of ophthalmic disorders that are associated with a neurodegenerative or trauma disorder is also... Agent: Morrison & Foerster LLP

20100273893 - Protective effect of thymoquinone in spesis: The present invention refers to thymoquinone, a main constituent of the volatile oil of Nigella sativa, and its protective effect against sepsis syndrome morbidity, mortality and associated organ dysfunctions. In particular, the present invention refers to thymoquinone for use in the prevention and/or treatment of sepsis syndrome. The present invention... Agent: Lowe Hauptman Ham & Berner, LLP

20100273894 - Treatment of leber's hereditary optic neuropathy and dominant optic atrophy with tocotrienol quinones: The present invention relates to methods of treating Leber's hereditary optic neuropathy and dominant optic atrophy with tocotrienol quinones, including alpha-tocotrienol quinone, in order to alleviate symptoms of the disease.... Agent: Morrison & Foerster LLP

20100273895 - Formulations of cannabidiol and prodrugs of cannabidiol and methods of using the same: Described herein are pharmaceutical compositions comprising a cannabinoid, such as cannabidiol or a cannabidiol prodrug, which is metabolized to cannabidiol, and a penetration enhancer. Also described herein are methods of using the same. One embodiment described herein relates to the transdermal or topical administration of pharmaceutical compositions comprising a cannabinoid,... Agent: Mayer Brown LLP

20100273896 - Method for producing products with water clusters: A method of producing products includes diluting a mater in a quality water as a dilution water a plurality of times until solid stable water clusters are formed having a plurality of water molecules connected with one another by electrical dipole interaction via internal electric field of ions and having... Agent: I. Zborovsky

20100273897 - Aqueous fungicidal composition and use thereof for combating harmful microorganisms: m

  
10/21/2010 > patent applications in patent subcategories. categorized by USPTO classification

20100267609 - Compounds which inhibit beta-secretase activity and methods of use thereof: Compounds inhibit memapsin 2 β-secretase activity and selectively inhibit memapsin 2 β-secretase activity relative to memapsin 1 β-secretase activity. The compounds are employed in methods to inhibit memapsin 2 β-secretase activity, in the treatment of Alzheimer's disease, in the inhibition of hydrolysis of a β-secretase site of a β-amyloid precursor... Agent: Morrison & Foerster LLP

20100267613 - Hypoallergenic cereal protein and uses thereof: A partial hydrolysate of cereal protein wherein the hydrolysate has a degree of hydrolysis between 9 and 18%, products containing such a partial hydrolysate and a method for the primary prevention of allergic reactions to cereal protein in a young mammal using such a partial hydrolysate are disclosed.... Agent: K&l Gates LLP

20100267608 - Modifications of cupredoxin derived peptides and methods of use thereof: The present invention provides modified cupredoxin derived peptides with pharmacologic activity that have improved pharmacokinetic properties, and methods to use them to treat mammals suffering from various conditions related to the pharmacologic activities. Modifications of the cupredoxin derived peptides include amino acid sequence variants and structural derivations that increase the... Agent: Don J. Pelto Sheppard, Mullin, Richter & Hampton LLP

20100267610 - Polypeptide comprising a knottin protein moiety: A polypeptide, with an amino acid sequence different from that of knottin protein, having a scaffold moiety with a helix moiety inserted in the scaffold moiety is described. The scaffold moiety comprises a knottin protein, or a fragment of knottin protein.... Agent: Mdip LLC

20100267612 - Sustained release composition containing sdf-1: An object of the present invention is to provide a sustained release composition containing SDF-1. The present invention provides a sustained release composition containing (1) SDF-1 and (2) a hydrogel containing modified gelatin having a carboxyl group and/or a sulfo group. Since the composition can release SDF-1, a chemokine which... Agent: Fitch, Even, Tabin & Flannery

20100267611 - Treatment of metabolic disease: The invention relates to metabolic disease, including non alcoholic fatty liver disease, to risk factors associated with same and to phospholipid-containing compositions.... Agent: Schwegman, Lundberg & Woessner, P.A.

20100267614 - Prodrugs of peripheral phenolic opioid antagonists: Compounds of formula (I), in which X, Y, R1, R2, n, R3 and R4 have the meanings given in the specification, are useful as pro-drugs of peripheral phenolic opioid antagonists.... Agent: Pharmacofore, Inc. Bozicevic, Field & Francis LLP

20100267615 - Methods for treatment and/or prevention of a disease associated with vascular leak: The present invention is directed to methods for treatment and/or prevention of a disease associated with vascular leak in a patient comprising administering to the patient an effective amount of SEQ ID NO: 1.... Agent: Hoffmann & Baron, LLP

20100267616 - Acute respiratory syndromes: Substance P or its analogs are useful for treating and protecting against acute respiratory syndromes including ARDS and SARS. The active agents can be administered via inhalation therapy, intravenously, intramuscularly, sublingually, or by other methods. Disease indicia are reduced by substance P treatment.... Agent: Jones Day

20100267617 - Methods and compositions for mycoplasma pneumoniae exotoxins: The present invention provides a Mycoplasma pneumoniae community acquired respiratory distress syndrome (CARDS) toxin, biologically active fragments/domains of the CARDS toxin, antibodies to the CARDS toxin and nucleic acids encoding the CARDS toxin. Also provided are methods of diagnosing, treating and/or preventing infection by Mycoplasma pneumoniae using the compositions provided... Agent: Myers Bigel Sibley & Sajovec

20100267619 - Methods and compositions for treatment of atherosclerosis: The present invention provides methods and compositions for treating subject having atherosclerosis. The invention provides a method comprising administering to a subject having atherosclerosis an effective amount of insulin like growth factor-1 (IGF-1), wherein the administering is effective to treat atherosclerosis in the subject. The invention also provides kits for... Agent: Tulane University Mr. Jacob Maczuga

20100267620 - Methods for slowing senescence and treating and preventing diseases associated with senescence: The present invention relates to a method for slowing, preventing or delaying senescence or treating or preventing a disease associated with senescence by administering a therapeutically effective amount of at least one physiological agent that decreases or regulates the blood level, production, function or activity of LH or FSH, or... Agent: Covington & Burling, LLP Attn: Patent Docketing

20100267618 - Methods for treating congestive heart failure: The invention features methods of treating or preventing congestive heart failure by administering a polypeptide containing an epidermal growth factor-like domain encoded by a neuregulin gene.... Agent: Klauber & Jackson

20100267621 - Antimicrobial compounds and formulations: The invention relates to the use of a molecule comprising a backbone of 2 to 35 non-hydrogen atoms in length, having covalently attached thereto at least two bulky and lipophilic groups and having at least one more cationic than anionic moiety, in the manufacture of a medicament for destabilising microbial... Agent: Rothwell, Figg, Ernst & Manbeck, P.C.

20100267622 - Methods to activate or block the hla-e/qa-1 restricted cd8+ t cell regulatory pathway to treat immunological disease: Methods are provided for inhibiting or enhancing down-regulation of an antigen-activated HLA-E+ T cell by an HLA-E-restricted CD8+ T cell comprising contacting the HLA-E* T cell and CD8+ T cell with an agent which inhibits or enhances, respectively, binding between (i) T cell receptor (TCR) on the surface of the... Agent: Cooper & Dunham, LLP

20100267623 - Peptides with capacity to bind to scurfin and applications: t

20100267624 - Vancomycin and teicoplanin anhydrous formulations for topical use: The invention concerns pharmaceutical anhydrous formulation for topical use comprising Vancomycin, Vancomycin Hydrochloride, or Teicoplanin, and Dimethylsulfoxide. In a preferred embodiment the formulation further comprises one or more glycols and/or ethers thereof, and optionally one or more fatty acids triglycerides and/or the polyoxyethylene derivative thereof. The use of Dimethylsulfoxide in... Agent: Katten Muchin Rosenman LLP (c/o Patent Administrator)

20100267625 - Novel bacillus thuringiensis gene with coleopteran activity: The invention provides nucleic acids, and variants and fragments thereof, obtained from strains of Bacillus thuringiensis encoding polypeptides having pesticidal activity against insect pests, including Coleoptera. Particular embodiments of the invention provide isolated nucleic acids encoding pesticidal proteins, pesticidal compositions, DNA constructs, and transformed microorganisms and plants comprising a nucleic... Agent: Pioneer Hi-bred International, Inc.

20100267626 - Methods and compositions for measuring wnt activation and for treating wnt-related cancers: The present application describes methods of regulating or modulating (e.g., antagonizing or inhibiting) Wnt signaling by administering Axin stabilizers. The application also describes methods of using Axin stabilizers described herein for the treatment, diagnosis, prevention, and/or amelioration of Wnt signaling-related disorders.... Agent: Novartis Institutes For Biomedical Research, Inc.

20100267627 - Support for protein transfer, protein transfer agent using the support, protein transfer method, cell having protein transferred thereinto and method of producing the same: A protein introduction method with which protein can be introduced into cells with excellent safety is provided. A target protein is supported on a carrier for protein introduction that is made from a clay mineral, and by adding this to cells it is possible to introduce the target protein into... Agent: Hamre, Schumann, Mueller & Larson, P.C.

20100267628 - Analogs of gastric inhibitory polypeptide and their use for treatment of diabetes: The present invention provides peptides which stimulate the release of insulin. The peptides, based on GIP 1-42 include substitutions and/or modifications which enhance and influence secretion and/or have enhanced resistance to degradation. The invention also provides a process of N terminally modifying GIP and the use of the peptide analogues... Agent: K&l Gates LLP

20100267629 - Enterostatin as therapeutic agent for hypoglycemia: It has been discovered that enterostatin injections into mice caused an increase in blood glucose levels within 15 minutes of injection, and the glucose levels remained high for up to an hour after injection. In addition, mice injected with enterostatin showed less of an initial decrease in blood glucose following... Agent: Patent Department Taylor, Porter, Brooks & Phillips, L.l.p

20100267631 - Apolipoprotein a-i mimics: Provided are peptides, compositions thereof, and methods for treating or preventing dyslipidemia, a cardiovascular disease, endothelial dysfunction, a macrovascular disorder, or a microvascular disorder.... Agent: Wilson, Sonsini, Goodrich & Rosati

20100267630 - Use of leptin in the prevention of unhealthy food habits and cardiovascular diseases: The present invention is addressed to the use of leptin, a fragment of leptin or a mimetic product of leptin action, in the preparation of a pharmaceutical composition, a food composition and/or a nutritional supplement for the prevention of unhealthy food habits and/or cardiovascular disorders during adulthood.... Agent: Moore & Van Allen PLLC

20100267632 - Treatment of neurodegenerative disorders: A method of treating neurodegenerative disorders of the brain and spinal cord is disclosed. The therapeutic agent is a polyethylene glycol linked protein.... Agent: Fulbright & Jaworski, LLP

20100267633 - N-(4-oxo-3,4-dihydroquinazolin-2yl) butanamides as androgen receptor modulators: The invention relates to substituted N-(4-oxo-3,4-dihydroquinazolin-2-yl)butanamid derivatives which modulate androgen receptors to treat conditions such as: osteoporosis, peridontal disease, bone fracture, frailty, and sarcopenia.... Agent: Merck

20100267634 - Anti-viral compounds: Compounds effective in inhibiting replication of Hepatitis C virus (“HCV”) are described. This invention also relates to processes of making such compounds, compositions comprising such compounds, and methods of using such compounds to treat HCV infection.... Agent: Paul D. Yasger Abbott Laboratories

20100267636 - Use of cytochrome p450-metabolized drugs and grf molecules in combination therapy: Combination therapies comprising a drug metabolized by cytochrome P450 and a growth hormone (GH)-inducing compound (such as a GRF molecule) are described, in which there are no or substantially no drug interactions.... Agent: Fish & Richardson P.C.

20100267635 - Use of protease inhibitors and grf molecules in combination therapy: Combination therapies comprising a protease inhibitor and a growth hormone (GH)-inducing compound (such as a GRF molecule) are described, in which there are no or substantially no drug interactions.... Agent: Fish & Richardson P.C.

20100267637 - Treatment of melanoma with alpha thymosin peptides in combination with a kinase inhibitor: Melanoma or a metastasis thereof is treated in a human patient in a combination therapy which includes administering a melanoma-treating combination to a human melanoma patient during a treatment regimen, the combination including an alpha thymosin peptide and a kinase inhibitor.... Agent: Cooley LLP Attn: Patent Group

20100267638 - Exosite-directed thrombin inhibitors: Disclosed are an amino acid sequence of the human blood clotting factor Va, peptides containing such sequence, and additional peptides of interest that significantly inhibit thrombin generation. Also disclosed are pharmaceutical compositions containing these peptides and related therapeutic methods for inhibiting thrombin generation and treating blood coagulation disorders.... Agent: Rankin, Hill & Clark LLP

20100267639 - Treatment of osteoarthritis: This invention relates to methods of treatment of osteoarthritis, and especially to treatment of this condition with cyclic peptidic and peptidomimetic compounds which have the ability to modulate the activity of G protein-coupled receptors. The compounds preferably act as antagonists of the C5a receptor, and are active against C5a receptors... Agent: Haynes And Boone, LLPIPSection

20100267640 - Method of attenuating neurogenic swelling or neurogenic inflammation: The present invention provides a method of attenuating the formation or reducing the severity of neurogenic swelling and/or neurogenic inflammation in the tissue of a patient via applying a composition comprising a hydrophilic foam substrate and a polymeric hydrophilic agent to a portion of the surface of the skin in... Agent: Leydig Voit & Mayer, Ltd

20100267641 - Prognostic tests for development of dermal stretch marks and implications for the preventative treatment thereof: Various methods of assessing the regenerative potential of dermal tissue in a patient may be determined and methods to determine the potential development of stretch marks in a patient are provided. Through the analysis of a series of dermal tissue samples, a method of monitoring the aging process of the... Agent: Pepper Hamilton LLP

20100267642 - Use of complex forms of calmodulin-like skin protein clsp: r

20100267643 - Chemosensory receptor ligand-based therapies: Provided herein are compositions and methods for treating diabetes, obesity, and other metabolic diseases, disorders or conditions with chemosensory receptor ligands. Also provided herein are pharmaceutical compositions useful for the methods of the present invention.... Agent: Wilson, Sonsini, Goodrich & Rosati

20100267644 - Cystatin c as an antagonist of tgf-beta and methods related thereto: Disclosed are Cystatin C (CysC) homologues, including CystC homologues that act as antagonists or inhibitors of transforming growth factor-β (TGF-β). Also disclosed are methods to identify CystC homologues that are antagonists or inhibitors of TGF-β and compositions and therapeutic methods using CystC and homologues thereof to regulate the activity of... Agent: Sheridan Ross PC

20100267645 - Methods and compositions for treating ocular disease: The use of collectins and/or surfactant proteins for the treatment and prevention of ocular disease.... Agent: Fenwick & West LLP

20100267647 - Modulating photoreactivity in a cell: Photoreactivity in a cell is modulated by incorporating an isolated optical trigger on the surface or in the membrane of the cell. Exposure of a cell bearing incorporated optical triggers causes the generation of a measurable physiological signal.... Agent: Frank S. Digiglio, Esq. Scully, Scott, Murphy & Presser, P.C.

20100267646 - Trophic factor for the treatment of retinal degenerative diseases: This invention relates to methods and compositions for detection and treatment of retinal degenerative diseases. In particular, the invention relates to polypeptides that can protect against cone degeneration, nucleic acid molecules that encode such polypeptides, and antibodies that recognize said polypeptides.... Agent: Mcandrews Held & Malloy, Ltd

20100267648 - Methods and materials relating to stem cell growth factor-like polypeptides and polynucleotides: The invention provides novel polynucleotides and polypeptides encoded by such polynucleotides and mutants or variants thereof that correspond to a novel human secreted stem cell growth factor-like polypeptides. Other aspects of the invention include vectors containing processes for producing novel human secreted stem cell growth factor-like polypeptides, and antibodies specific... Agent: Fulbright & Jaworski L.L.P.

20100267649 - Vascular adhesion molecules and modulation of their function: The invention relates to new polypeptides in isolated form belonging to a subfamily of the human immunoglobulin superfamily, which polypeptide shows at least 70% sequence homology with the amino acid sequence of the murine Confluency Regulated Adhesion Molecules 1 or 2 (CRAM-1 or CRAM-2) as depicted in FIG. 3, upper... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association

20100267650 - Dual chain synthetic heparin-binding growth factor analogs: The invention provides synthetic heparin-binding growth factor analogs having two peptide chains each branched from a branch moiety, such as trifunctional amino acid residues, the branch moieties separated by a first linker of from 3 to about 20 backbone atoms, which peptide chains bind a heparin-binding growth factor receptor and... Agent: Peacock Myers, P.C.

20100267651 - T cell antigen receptor peptides: e

20100267652 - Method of inhibiting abcg2 and related treatments: Disclosed are methods of enhancing the chemotherapeutic treatment of tumor cells, reducing resistance of a cancer cell to a chemotherapeutic agent, a method of inhibiting ABCG2 or MRP1 in a mammal afflicted with cancer, and a method of increasing the bioavailability of an ABCG2 substrate drug in a mammal. The... Agent: Leydig, Voit & Mayer, Ltd.

20100267653 - Use of coumarin derivatives in antifungal therapy: The invention provides coumarin compounds, in particular glycosidic coumarin compounds, useful in the treatment of dermatophyte fungal infections.... Agent: Morgan, Lewis & Bockius LLP (sf)

20100267654 - Rifamycin derivatives: R is hydrogen or acetyl; R1 and R2 are independently selected from the group consisting of hydrogen, (C1-4)alkyl, benzyloxy, mono- and di-(C1-3)alkylamino-(C1-4)alkyl, (C1-3)alkoxy, (C1-4)alkyl, hydroxy-methyl, hydroxy-(C2-4)-alkyl, and nitro or R1 and R2 taken together with two consecutive carbon atoms of the pyridine nucleus form a benzene ring optionally substituted by... Agent: Techlaw LLP

20100267655 - Glycosylated warfarin analogs and uses thereof: The present invention discloses a set of glycosylated warfarin analogs which are useful as anti-tumor or anti-metastatic agents and as reagents for studying sugar uptake in cells.... Agent: Quarles & Brady LLP

20100267807 - Alleviating neuropathic pain with eets and seh inhibitors: The invention discloses methods of using cis-epoxyeicosantrienoic acids (“EETs”), inhibitors of soluble epoxide hydrolase (“sEH”), or a combination of an EET and an inhibitor of sEH, to alleviate neuropathic pain in subjects suffering from such pain.... Agent: Townsend And Townsend And Crew, LLP

20100267808 - Bispecific antisense oligonucleotides that inhibit igfbp-2 and igfbp-5 and methods of using same: Bispecific antisense oligonucleotides which consist essentially of a sequence of bases that is complementary to portions of both the gene encoding human IGFBP-2 and the gene encoding human IGFBP-5 are useful in as antisense therapeutics in the treatment of endocrine-regulated cancers.... Agent: Larson & Anderson, LLC

20100267801 - Cyclohexyl sulphones for treatment of cancer: Sulphones of formula (I) are disclosed for use in treatment of cancer.... Agent: Merck

20100267802 - Delivery method: The present invention relates, in general, to RNA silencing and, in particular, to a method of effecting targeted delivery of an RNA silencing moiety using a targeting moiety that binds to a cell surface receptor and mediates internalization of the RNA silencing moiety to be accessible to Dicer. Also provided... Agent: Nixon & Vanderhye, PC

20100267804 - Differential expression of micrornas in nonfailing versus failing human hearts: The present invention discloses specific miRNAs as novel biomarkers and therapeutic targets in the treatment of heart failure. Methods of treating or preventing heart failure in a subject by administering mimics or inhibitors of these particular miRNAs are disclosed. A method of diagnosing or prognosing heart failure in a subject... Agent: Cooley LLP Attn: Patent Group

20100267809 - Double stranded nucleic acid targeting low copy promoter-specific rna: The present invention relates to transcriptional gene silencing (TGS) in mammalian, including human, cells that is mediated by small interfering RNA (siRNA) molecules. The present invention also relates to a double stranded nucleic acid that directs methylation of histones associated with target genes that produce low copy promoter-specific RNA. It... Agent: Rothwell, Figg, Ernst & Manbeck, P.C.

20100267806 - Lipid formulated compositions and methods for inhibiting expression of eg5 and vegf genes: This invention relates to compositions containing double-stranded ribonucleic acid (dsRNA) in a lipid formulation, and methods of using the compositions to inhibit the expression of the Human kinesin family member 11 (Eg5) and Vascular Endothelial Growth Factor (VEGF), and methods of using the compositions to treat pathological processes mediated by... Agent: Alnylam/fenwick

20100267810 - Methods and compositions for treating neurological disease: This invention relates to methods and compositions for treating neurological disease, and more particularly to methods of delivering iRNA agents to neural cells for the treatment of neurological diseases.... Agent: Lahive & Cockfield, LLP Floor 30, Suite 3000

20100267803 - Regulators of fat metabolism as anti-cancer targets: Embodiments of the invention provide methods of identifying agents that reduce or prevent the proliferation of breast cancer cells, or kill them, in particular by interfering with the expression of the transcription factors NR1D1 and PPARγ or the expression of genes whose transcription they activate or the activity of the... Agent: Medlen & Carroll, LLP Suite 350

20100267811 - Rnai-related inhibition of tnfa signaling pathway for treatment of ocular angiogenesis: RNA interference is provided for inhibition of tumor necrosis factor α (TNFα) by silencing TNFα cell surface receptor TNF receptor-1 (TNFR1) mRNA expression, or by silencing TNFα converting enzyme (TACE/ADAM17) mRNA expression. Silencing such TNFα targets, in particular, is useful for treating patients having a TNFα-related condition or at risk... Agent: Alcon

20100267805 - Targeting opposite strand replication intermediates of single-stranded viruses by rnai: The invention relates to methods and compositions for modulating viral replication through double-stranded RNA-mediated gene silencing (RNAi), wherein the antiviral methods and compositions preferentially target opposite strand replication intermediates of single-stranded RNA viruses.... Agent: David S. Resnick

20100267812 - Gene therapy for amyotrophic lateral sclerosis and other spinal cord disorders: This disclosure provides methods and compositions for treating disorders or injuries that affect motor function and control in a subject. In one aspect, the invention a transgene product is delivered to a subject's spinal cord by administering a recombinant neurotrophic viral vector containing the transgene to the brain. The viral... Agent: Genzyme Corporation Legal Department

20100267816 - Human anti-amyloid beta peptide antibody and fragment of said antibody: A human anti-amyloid β peptide (hereinafter referred to as “Aβ”) antibody that binds to Aβ to thereby inhibit aggregation of Aβ molecules, and a fragment of said antibody are provided. The antibody and a fragment thereof according to the present invention, comprising a variable region of a human-derived anti-Aβ antibody,... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, L.L.P.

20100267813 - Oligomeric compounds and compositions for use in modulation of small non-coding rnas: Compounds, compositions and methods are provided for modulating the expression and function of small non-coding RNAs. The compositions comprise oligomeric compounds, targeted to small non-coding RNAs. Methods of using these compounds for modulation of small non-coding RNAs as well as downstream targets of these RNAs and for diagnosis and treatment... Agent: Pepper Hamilton LLP

20100267815 - Pfkfb4 inhibitors and methods of using the same: Methods of reducing expression of 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase 4 (PFKFB4) and methods of treating a cancer in a cell are provided, the methods including contacting a cell with an effective amount of a PFKFB4 inhibitor. Short hairpin RNA (shRNA) and small interfering RNA (siRNA) inhibitors of PFKFB4 and their methods of use... Agent: Dinsmore & Shohl LLP

20100267814 - Targeting micrornas for the treatment of liver cancer: Provided herein are methods for the treatment of liver cancer. These methods encompass the administration of a compound comprising a modified oligonucleotide, wherein the modified oligonucleotide is targeted to a miRNA. Also provided herein are compositions for the treatment of liver cancer. Such compositions include compounds comprising a modified oligonucleotide,... Agent: Pepper Hamilton LLP

20100267656 - Myeloid differentiation inducing agents: Myeloid differentiating agents can be used in the treatment of myeloid disorders.... Agent: Tarolli, Sundheim, Covell & Tummino, LLP

20100267657 - Antimetabolite agent combinations in the treatment of cancer: A method treating cancer in a subject comprises administering to the subject a therapeutically effective amount of an antimetabolite agent that induces formation of AP sites in cancer cells of the subjects and an amount AP endonuclease inhibitor effective to potentiate the cytotoxicity of the antimetabolite agent to the cancer... Agent: Tarolli, Sundheim, Covell & Tummino, LLP

20100267658 - Trehalulose-containing composition, its preparation and use: The present invention relates to a trehalulose-containing composition, its preparation and use.... Agent: Ostrolenk Faber Gerb & Soffen

20100267663 - A composition for cicatrisation processes in the treatment of hypertrophic scars and for improving the biomechanical properties of the cutis: This invention concerns a composition for pharmaceutical and/or cosmetic and/or in the form of medical device, in particular for the prevention and treatment of hypertrophic scars and/or cheloids, to inhibit any fibrosclerotic process and to improve the biomechanical properties of the skin and to obstruct retraction to cicatrisation of the... Agent: Mcglew & Tuttle, PC

20100267662 - Avenanthramide-containing compositions: Methods and compositions for treating or preventing a skin condition, an inflammation, an irritation or an allergy associated with an ectoparasitic infection or infestation on an animal. The methods involve applying to the skin of the animal a pharmaceutical composition that contains a therapeutically effective amount of one or more... Agent: Akerman Senterfitt

20100267661 - Beta glucans and methods of use thereof: The present invention relates to therapeutic uses of beta glucan for treating cancer, cytopenia, and symptoms associated with negative side effects of chemotherapy. As such, the current invention provides methods of using beta glucan for treating cancer, for increasing hematopoiesis, and for improving the quality of life of subjects undergoing... Agent: Dla Piper LLP (us)

20100267660 - Efficient production of oligosaccharides using metabolically engineered microorganisms: The present invention relates to the enzymatic synthesis of oligosaccharides, particularly, sialylated oligosaccharides comprising the carbohydrate moeities of the gangliosides GM3, GD3, and GT3.... Agent: Foley And Lardner LLP Suite 500

20100267659 - Extract obtained from orchidaceae plants, method for producing the extract, and external agent for skin comprising the extract: This invention relates to an extract obtained from a plant of the genus Odontoglossum of the family Orchidaceae, or from a plant derived from a hybrid plant of the genus Odontoglossum and the genus Cochlioda, to a method for preparing the extract, and to an external agent for skin comprising... Agent: Sughrue Mion, PLLC

20100267664 - Ophthalmic compositions containing polysaccharide-borate gelling system: Topical ophthalmic compositions that form a gel or partial gel upon application to the eye are described. The compositions are particularly useful as artificial tears and ocular lubricants, but may also be utilized for the topical delivery of pharmaceutically active compounds to the eye. The compositions contain a polysaccharide/borate gelling... Agent: Alcon

20100267665 - Remedy for corneal diseases: The present invention provides a method for treating a corneal disease by administering to a patient in need of such treatment an effective amount of ozagrel or a salt thereof.... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, L.L.P.

20100267668 - 4-azetidinyl-1-heteroatom linked-cyclohexane antagonists of ccr2: wherein: X, R1, R2, R3, and R4 are as defined in the specification. The invention also comprises a method of preventing, treating or ameliorating a syndrome, disorder or disease, wherein said syndrome, disorder or disease is type II diabetes, obesity and asthma. The invention also comprises a method of inhibiting... Agent: Philip S. Johnson Johnson & Johnson

20100267669 - Heterocyclic cetp inhibitors: e

20100267670 - Novel heterocycle derivatives useful as selective androgen receptor modulators (sarms): The present invention is directed to novel heterocycle derivatives, pharmaceutical compositions containing them and their use in the treatment of disorders and conditions modulated by the androgen receptor.... Agent: Philip S. Johnson Johnson & Johnson

20100267666 - Pyrrolopyrazine kinase inhibitors: e

20100267667 - Telomerase activating compounds and methods of use thereof: The present invention is directed to use of a series of compounds and compositions comprising the same for activating telomerase and treating diseases, disorders and/or conditions related thereto.... Agent: Lucas & Mercanti, LLP

20100267671 - Compositions and methods for apoptosis modulators: The present invention includes and relates generally to compounds which modulate apoptosis in cells. The present invention also provides pharmaceutical compositions containing these compounds, methods of making these compounds, and methods of using these compounds and pharmaceutical compositions for treatment of diseases associated with irregular apoptosis in cells.... Agent: Cooley LLP Attn: Patent Group

20100267672 - Novel compounds of reverse-turn mimetics, method for manufacturing the same and use thereof: Disclosed are novel reverse turn mimetics based on the framework of pyrazino-triazinone, and the use thereof in the treatment of cancers, particularly, acute myeloid leukemia. A method is also provided for manufacturing the reverse turn mimetics on a mass scale.... Agent: Seed Intellectual Property Law Group PLLC

20100267673 - Protein phosphatase 2a-activating agents: s

20100267674 - Calcium/sodium salt of inositol tripyrophosphate as an allosteric effector of hemoglobin: The present invention relates to mixed calcium/sodium salt of inositol tripyrophosphate, methods of preparing and methods of use. The mixed calcium/sodium salt may be a monocalcium tetrasodium salt of inositol tripyrophosphate. Methods of use include administering the above salts in an effective amount to treat diseases caused by hypoxia or... Agent: Ropes & Gray LLP

20100267675 - Compositions comprising sphingosine 1 phosphate (s1p) receptor modulators: The present invention relates to stable compositions comprising a sphingosine 1 phosphate (S1P) receptor modulator, suitable for use as a dosage form. The S1P receptor modulators are typically sphingosine analogues, such as 2-substituted 2-amino-propane-1,3-diol or 2-amino-propanol derivatives, e.g. a compound comprising a group of formula Y.... Agent: Novartis Corporate Intellectual Property

20100267676 - Gamma-amino-butyric acid derivatives as gabab receptor ligands: Gamma-amino-butyric acid derivatives that are GABAB receptor ligands, pharmaceutical compositions comprising such derivatives, and methods of using such derivatives and pharmaceutical compositions thereof for treating diseases are disclosed.... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20100267677 - Compositions and methods for synergistic manipulation of plant and insect defenses: This invention relates to the control of plant pests, such as aphid and whitefly by treating plants with a compound which inhibits the plant pest's ability to overcome plant defence responses, such as piperonyl butoxide or propyl gallate, in combination with a compound which activates plant defence responses, such as... Agent: Banner & Witcoff, Ltd.

20100267678 - Flux-enabling compositions and methods for dermal delivery of drugs: The present invention is drawn to adhesive solidifying formulations, methods of drug delivery, and solidified layers for dermal delivery of a drug. The formulation can include a drug, a solvent vehicle, and a solidifying agent. The solvent vehicle can include a volatile solvent system comprising at least one volatile solvent,... Agent: Thorpe North & Western, LLP.

20100267679 - Pharmaceutical combination of medication to be used by patients for the purpose of preventing or reducing the evolution of atherosclerosis and thus preventing coronary heart disease and cerebro-vascular accidents.: Arteriosclerosis is a general term describing any hardening (and loss of elasticity) of medium or large arteries. Arteriolosclerosis is any hardening (and loss of elasticity) of arterioles (small arteries). Atherosclerosis is a hardening of an artery specifically due to an atheromatous plaque. Therefore, atherosclerosis is a form of arteriosclerosis: it... Agent: Jacques Benoit

20100267680 - Use of at least one oxime derivative of cholest-4-en-3-one as antioxidants: The invention relates to the use of at least one oxime derivative of cholest-4-en-3-one as antioxidants in the cosmetics and food fields, and as antioxidant preservatives that can be used, in particular, in cosmetic, food and pharmaceutical products.... Agent: Browdy And Neimark, P.l.l.c. 624 Ninth Street, Nw

20100267682 - Corticosteroids to treat epothilone or epothilone derivative induced diarrhea: Epothilone derivatives are co-administered with an antidiarrheal agent, e.g., a corticosteroid, or a glucocorticoid steroid in the treatment of a proliferative disease.... Agent: Novartis Corporate Intellectual Property

20100267681 - Fat or oil composition: o

20100267683 - Pharmaceutical composition comprising peroxided oil and cholesterol and uses thereof in medical field: The present invention concerns a pharmaceutical composition comprising peroxided oil and cholesterol to be used in medical field, for example, in the treatment of tumours, viral diseases, ulcers and dermatitis.... Agent: Arent Fox LLP

20100267684 - Use of biological surfactant as anti-inflammatory agent and tissue preservative solution: The present invention relates to a use of a biological surfactant as an anti-inflammatory agent and a tissue preservative solution. More particularly, the present invention is directed to an anti-inflammatory agent and a tissue preservative solution comprising a biological surfactant which blocks a reaction of a proinflammatory factor with a... Agent: Roberts Mlotkowski Safran & Cole, P.C. Intellectual Property Department

20100267685 - Methods for the prophylaxis and/or treatment of thromboembolic disorders by combination therapy with substituted oxazolidinones: The invention relates to combinations of A) oxazolidinones of formula (I) and B) other active ingredients, to a method for producing said combinations and to the use thereof as medicaments, in particular for the treatment and/or prophylaxis of thrombo-embolic diseases.... Agent: Connolly Bove Lodge & Hutz, LLP

20100267686 - Carbacephem beta-lactam antibiotics: e

20100267687 - Phenylpyrazole derivatives:

20100267688 - 4-azetidinyl-1-heteroaryl-cyclohexane antagonists of ccr2: wherein: X, R1, R2, R3, and R4 are as defined in the specification. The invention also comprises a method of preventing, treating or ameliorating a syndrome, disorder or disease, wherein said syndrome, disorder or disease is type II diabetes, obesity and asthma. The invention also comprises a method of inhibiting... Agent: Philip S. Johnson Johnson & Johnson

20100267689 - 4-azetidinyl-1-phenyl-cyclohexane antagonists of ccr2: wherein: X, R1, R2, R3, and R4 are as defined in the specification. The invention also comprises a method of preventing, treating or ameliorating a syndrome, disorder or disease, wherein said syndrome, disorder or disease is type II diabetes, obesity and asthma. The invention also comprises a method of inhibiting... Agent: Philip S. Johnson Johnson & Johnson

20100267690 - Tricyclic guanidine derivatives as sodium-proton exchange inhibitors: are disclosed, wherein U is C(O), CRaRb, O, NRa or S(O)m; V is CRaRb or NRa; W is S(O)m; wherein Ra is H, alkyl, cycloalkyl, alkenyl or aralkyl; Rb is H, alkyl, OH, ORa or OCORa, and m is the integer 0, 1 or 2; R1, R2, R3, R4, R5,... Agent: Merchant & Gould PC

20100267691 - Combinations comprising 3-phenylsulfonyl-8-piperazinyl-1yl-quinoline: e

20100267692 - smac mimetic compounds as apoptosis inducers: The present invention relates to compounds conformationally constrained mimetics of Smac with function as inhibitors of Inhibitor of Apoptosis Proteins (IAPs), the invention also relates to the use of these compounds in therapy, wherein the induction of apoptotic cell death is beneficial, especially in the treatment of cancer, alone or... Agent: Nixon & Vanderhye, PC

20100267693 - Orodispersible pharmaceutical composition of ivabradine: The invention relates to a solid orodispersible pharmaceutical composition of ivabradine, characterised in that it comprises ivabradine or a pharmaceutically acceptable salt thereof and granules consisting of co-dried lactose and starch.... Agent: The Firm Of Hueschen And Sage

20100267694 - S-mirtazapine for the treatment of hot flush: The invention provides a method of treatment of hot flush with S-mirtazapine and the use of S-mirtazapine for the manufacture of a medicament for the treatment of hot flush.... Agent: Organon Usa, Inc. C/o Merck

20100267695 - Fused indane compound: [Means for Solution] The present inventors have studied a compound having an NMDA receptor antagonistic action, and confirmed that the fused indane compound of the present invention has an excellent NMDA receptor antagonistic action, thereby completed the present invention. The fused indane compound of the present invention has an excellent... Agent: Fitzpatrick Cella Harper & Scinto

20100267696 - Amido-thiophene compounds and their use as 11-beta-hsd1 inhibitors: The present invention pertains generally to the field of therapeutic compounds. More specifically the present invention pertains to certain amido-thiophene compounds that, inter alia, inhibit 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1). The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both... Agent: Swanson & Bratschun, L.L.C.

20100267697 - Ion channel modulators: and pharmaceutically acceptable salts, hydrates, and esters thereof, wherein Ar, R1, R2, R3, p, and X are defined herein. The present teachings also provide processes for producing said compounds and their pharmaceutically acceptable salts, hydrates and esters, and methods of treating a pathological condition or disorder, or alleviating a symptom... Agent: Wyeth LLC Patent Law Group

20100267698 - Benzimidazole and pyridylimidazole derivatives: This invention also relates to the use of benzimidazoles, pyridylimidazoles and related bicyclic heteroaryl compounds of Formula I in combination with one or more other CNS agents to potentiate the effects of the other CNS agents. Additionally this invention relates to the use such compounds as probes for the localization... Agent: Mcdonnell Boehnen Hulbert & Berghoff LLP

20100267702 - Bisbenzamidines and bisbenzamidoximes for the treatment of human african trypanosomiasis: Disclosed are bisbenzamidine and bisbenzamidoxime compounds useful for treatment of trypanosomiasis. The compounds disclosed are useful for treating mammals infected with parasitic hemoflagellates, in particular Trypanosoma brucei gambiense and Trypanosoma brucei rhodesiense.... Agent: Adams And Reese LLP

20100267699 - Chemical compounds - 643: s

20100267700 - Immunosuppressive agent and anti-tumor agent comprising heterocyclic compound as active ingredient: A novel method for immunosuppressive in a mammal suffering from an immune disease, including administering to the mammal a therapeutically effective amount of a heterocyclic compound represented by the general formula (I) (wherein X or other variables are as defined in the specification) or a pharmaceutically acceptable salt thereof is... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, L.L.P.

20100267701 - Substituted pyridyl amide compounds as modulators of the histamine h3 receptor: Certain substituted pyridyl amide compounds are histamine H3 receptor modulators useful in the treatment of histamine H3 receptor-mediated diseases.... Agent: Philip S. Johnson Johnson & Johnson

20100267703 - 4-amino-1,2,3-benzoxathiazine-derivatives as pesticides: r

20100267704 - Autophagy inducing compounds and uses thereof in treating autophagy associated diseases: This invention pertains to a class of autophagy inducing compounds that treat diseases caused by misfolded protein aggregates and a screening method for identifying these compounds.... Agent: Foley Hoag, LLP (w/huv Hmv) Patent Group

20100267705 - Pharmaceutical formulation containing lipophilic drugs and milk as a solubilizing/dispensing agent and method for the preparation thereof: The present invention relates to an improved pharmaceutical composition and in particular to a pharmaceutical formulation for oral administration comprising a therapeutically effective quantity of a lipophilic active ingredient with milk as a solubilizing/dispersing agent and methods for the preparation thereof.... Agent: Akc Patents

20100267706 - Compounds, compositions and methods comprising pyridazine derivatives: The present invention relates to compounds, compositions and methods for treating a disease in an animal, which disease is responsive to inhibiting of functional cystic fibrosis transmembrane conductance regulator (CFTR) polypeptide by administering to a mammal in need thereof an effective amount of a compound defined herein (including those compounds... Agent: Foley & Lardner LLP

20100267708 - Glucokinase activators and pharmaceutical compositions containing the same as an active ingredient: The present invention relates to new compounds of formula (1) exhibiting excellent activity for glucokinase, and pharmaceutical compositions comprising the same as an active ingredient.... Agent: Birch Stewart Kolasch & Birch

20100267709 - Inhibitors of janus kinases: The instant invention provides for compounds that inhibit the four known mammalian JAK kinases (JAK1, JAK2, JAK3 and TYK2) and PDK1. The invention also provides for compositions comprising such inhibitory compounds and methods of inhibiting the activity of JAK1, JAK2, JAK3 TYK2 and PDK1 by administering the compound to a... Agent: Merck

20100267710 - N3 alkylated benzimidazole derivatives as mek inhibitors: and pharmaceutically acceptable salts and prodrugs thereof, wherein W, R1, R2, R7, R8, R9 and R10 are as defined in the specification. Such compounds are MEK inhibitors and useful in the treatment of hyperproliferative diseases, such as cancer and inflammation, in mammals. Also disclosed is a method of using such... Agent: Hogan Lovells US LLP

20100267707 - Tyrosine kinase inhibitors: The present invention relates to 4-indol-3-yl-N-phenylpyrimidin-2-amine derivatives, that are useful for treating cellular proliferative diseases, for treating disorders associated with MET activity, and for inhibiting the receptor tyrosine kinase MET. The invention also related to compositions which comprise these compounds, and methods of using them to treat cancer in mammals.... Agent: Merck

20100267711 - Method of enhancing cellular production of molecular chaperone, hydroxylamine derivatives useful for enhancing the chaperone production and the preparation thereof: e

20100267713 - 4,4-disubstituted piperidines: The application relates to 4,4-disubstituted piperidines of the general formula (I) and their salts, preferably their pharmaceutically acceptable salts, in which R2, has the meanings explained in the description, a process for their preparation and the use of these compounds as medicines, especially as renin inhibitors.... Agent: Novartis Institutes For Biomedical Research, Inc.

20100267712 - Isoindoline compounds for the treatment of spinal muscular atrophy and other uses: Disclosed is a compound of Formula (I) in which W and R1-R6 are defined herein. Also disclosed is a method of treating spinal muscular atrophy, as well as methods of using such compounds to increase SMN expression, increase EAAT2 expression, or increase the expression of a nucleic acid that encodes... Agent: Leydig, Voit & Mayer, Ltd.

20100267714 - Mif modulators: The invention provides novel heterocyclic compounds, pharmaceutical compositions and methods of treatment that modulate levels of MIF expression and treat disorders associated with high or low levels of MIF expression.... Agent: Coleman Sudol Sapone, P.C.

20100267715 - Polymorph form ii of tanaproget: Tanaproget polymorph Form II, processes for preparing tanaproget polymorph Form II, pharmaceutical compositions including tanaproget polymorph Form II, micronized tanaproget polymorph Form II, and processes for converting Form II to tanaproget Form I are provided. Also provided are methods of contraception, hormone replacement therapy, stimulation of food intake and treating... Agent: Howson & Howson LLP / Wyeth LLC

20100267716 - Methods of treating inflammations and infections with pyridinium salts: Compounds of pyridinium salts and methods of their use in medicine, particularly in the prophylaxis and treatment of inflammatory conditions, infectious conditions, as well as immune disorders are disclosed. The present invention also relates to methods of controlling fungi and/or bacteria.... Agent: Myers Bigel Sibley & Sajovec

20100267718 - Bicyclic heterocycles, pharmaceutical compositions containing these compounds, their use and processes for preparing them: Ra, Rb, Rc, Rd, X and n are defined as in claim 1, the tautomers, the stereoisomers, the mixtures thereof and the salts thereof, particularly the physiologically acceptable salts thereof with inorganic or organic acids which have valuable pharmacological properties, particularly an inhibiting effect on the signal transduction mediated by... Agent: Michael P. Morris Boehringer Ingelheim Usa Corporation

20100267717 - Novel heterocyclic nf-kb inhibitors: ,

20100267720 - crystalline forms of 2-hydroxy-3- [5- (morpholin- 4- ylmethyl) pyridin-2-yl] ih- indole- 5 -carbonitrile citrate: The present invention relates to new crystalline forms of 2-hydroxy-3-[5-(morpholin-4-ylmethyl)pyridin-2-yl]1H-indole-5-carbonitrile citrate, a Form D and a Form E, respectively, a process for their preparations, pharmaceutical formulations containing said compounds and to the use of said active compounds in therapy, and particularly to GSK3 related conditions and disorders.... Agent: Astra Zeneca Pharmaceuticals Lp Global Intellectual Property

20100267719 - Enhanced indolinone based protein kinase inhibitors: Alpha-hydroxy-omega-(2-oxo-indolylidenemethyl-pyrrole-3′-carbonyl)amino alkanoic acid and amide derivatives have enhanced and unexpected drug properties as inhibitors of protein kinases and are useful in treating disorders related to abnormal protein kinase activities such as cancer.... Agent: Schwegman, Lundberg & Woessner, P.A.

20100267721 - Heterocyclic h3 antagonists: Compound of formula (I) wherein W, X, Y, Z is —C(R′)═ or N; R1 is hydrogen or alkyl, V is N or C (i.e. carbon), A is a bond or an alkylene linker with 1 to 3 carbon atoms, with the proviso that when A is a bond, V must... Agent: High Point Pharmaceuticals, LLC

20100267722 - Novel proline derivatives: m

20100267723 - Imidazole substituted pyrimidines: wherein R1 is hydrogen or fluoro; R2 and R3 are independently selected from hydrogen or methyl, or a pharmaceutically acceptable salt thereof; pharmaceutical formulations containing said compound; the use of said compound in therapy; the use for the treatment of conditions associated with glycogen synthase kinase-3 related disorders, such as... Agent: Astra Zeneca Pharmaceuticals Lp Global Intellectual Property

20100267725 - Compounds, compositions and methods comprising 4n-substituted triazole derivatives: The present invention relates to compounds, compositions and methods for treating a disease in an animal, which disease is responsive to inhibiting of functional cystic fibrosis transmembrane conductance regulator (CFTR) polypeptide by administering to a mammal in need thereof an effective amount of a compound defined herein (including those compounds... Agent: Foley & Lardner LLP

20100267724 - S-triazole alpha-mercaptoacetanilides as inhibitors of hiv reverse transcriptase: A series of S-triazolyl α-mercaptoacetanilides having general structure (1) are provided, where Q is CO2H, CONR2, SO3H, or SO2NR2. The compounds inhibit several variants of the reverse transcriptase of HIV, and are useful in the treatment of HIV infections.... Agent: Wilson, Sonsini, Goodrich & Rosati

20100267726 - 2-aryl-acetic acids, their derivatives and pharmaceutical compositions containing them: Selected 2-arylacetic acids, their derivatives and pharmaceutical compositions that contain these compounds are useful in inhibiting chemotactic activation of neutrophils (PMN leukocytes) induced by the interaction of Interleukin-8 (IL-8) with CXCR1 and CXCR2 membrane receptors. The compounds are used for the prevention and treatment of pathologies deriving from said activation.... Agent: Birch Stewart Kolasch & Birch

20100267727 - Pharmaceutical formulations comprising neurotrophin mimetics: Methods and compounds for treating neurodegenerative and other disorders. Included is the administering to a subject in need thereof an effective amount of a compound having binding specificity for a p75NTR receptor molecule. Enhanced survival of neural and other cells has been observed.... Agent: Jenkins, Wilson, Taylor & Hunt, P. A.

20100267728 - 3-substituted-1,2,3-triazin-4-one's and 3 substituted 1,3-pyrimidinone's for enhancing glutamatergic synaptic responses: This invention relates to compounds, pharmaceutical compositions and methods for use in the prevention and treatment of cerebral insufficiency, including enhancement of receptor functioning in synapses in brain networks responsible for basic and higher order behaviors. These brain networks, which are involved in regulation of breathing, and cognitive abilities related... Agent: Coleman Sudol Sapone, P.C.

20100267729 - Fungicidal heterocyclic amines: Also disclosed are compositions containing the compounds of Formula 1 and methods for controlling plant disease caused by a fungal pathogen comprising applying an effective amount of a compound or a composition of the invention.... Agent: E I Du Pont De Nemours And Company Legal Patent Records Center

20100267730 - Novel compounds: This invention relates to imidazopyridazine substituted piperidine derivatives and their use as pharmaceuticals.... Agent: Glaxosmithkline Global Patents -us, Uw2220

20100267731 - Use of transforming growth factor-b receptor inhibitors to suppress ocular scarring: A pharmaceutical composition useful in the prevention of subconjunctival scarring that may occur after GFS comprising an effective amount of an ALK-5 inhibitor. Also disclosed is a method of treating disorder or condition of other ocular scarring or fibrosis including corneal haze and PVR that may develop after ocular surgery... Agent: Benesch, Friedlander, Coplan & Aronoff LLP Attn:IPDepartment Docket Clerk

20100267732 - Prognostic molecular markers for et-743 treatment: The present invention relates to the use of ecteinascidin 743 in human patients having certain molecular markers profile which has been associated with the outcome of ET-743 chemotherapy. In particular, the invention relates to the use of ecteinascidin 743 in patients having high expression levels of XPG mRNA or protein... Agent: King & Spalding

20100267733 - Synergistic modulation of microglial activation by nicotine and thc: Treatment of microglial cells with nicotine and THC synergistically attenuate the microglial activation. Using microglial activation, the combination of THC and nicotine interact synergistically reduced LPS induced TNF-α release, showing that the combination of THC and nicotine clinically have greater efficacy in reducing neuroinflammation with less side effects than either... Agent: Smith Hopen, Pa

20100267734 - N-[(3,5-dichlorophenyl)methyl]-2-(4-methyl-1-piperazinyl)-2-(1-naphthalenyl)ethanamide as ghrelin receptor modulator: processes for their preparation, intermediates useable in these processes, pharmaceutical compositions containing them and their use in therapy, for example as modulators of the growth hormone secretagogue receptor (also referred to as the ghrelin receptor or GHSR1a receptor) and/or for the treatment and/or prophylaxis of a disorder mediated by the... Agent: Glaxosmithkline Global Patents

20100267735 - Methods and compositions to enhance the efficacy of phosphodiesterase inhibitors: Methods for treatment of sexual dysfunction in men and women using combination of phosphodiesterase (PDE) type 5 inhibitors and 1-deprenyl or propargylamine compounds are described. Methods of reducing the dosage and preventing the side effects of PDE type5 inhibitors are also described. The methods comprise administering a therapeutically effect amount... Agent: Smith Hopen, Pa

20100267736 - Methods and compositions to enhance the efficacy of phosphodiesterase inhibitors: Methods for treatment of sexual dysfunction in men and women using combination of phosphodiesterase (PDE) type 5 inhibitors and 1-deprenyl or propargylamine compounds are described. Methods of reducing the dosage and preventing the side effects of PDE type5 inhibitors are also described. The methods comprise administering a therapeutically effect amount... Agent: Smith Hopen, Pa

20100267737 - 4-phenylpiperazine derivatives with functionalized linkers as dopamine d3 receptor selective ligands and methods of use: Dopamine D3 receptor antagonists and partial agonists are known to modulate the reinforcing and drug-seeking effects induced by cocaine and other abused substances. By introducing functionality into the butylamide linking chain of the 4-phenylpiperazine class of ligands, improved D3 receptor affinity and selectivity, as well as water solubility, is achieved.... Agent: Cantor Colburn LLP - National Institutes Of Health

20100267738 - Novel amide and amidine derivatives and uses thereof: The present invention relates to inhibitors of 11-β-hydroxysteroid dehydrogenase type 1 enzyme and their use in treatment of non-insulin dependent type 2 diabetes, insulin resistance, obesity, lipid disorders, metabolic syndrome, central nervous system disorders, and diseases and conditions that are related to excessive glucocorticoids.... Agent: Paul D. Yasger Abbott Laboratories

20100267739 - Treatment of affective disorders by the combined action of a nicotinic receptor agonist and a monoaminergic substance: The use of the combined action of a nicotinic acetylcholine receptor agonist and a monoaminergic substance for the treatment of affective disorders, as well as pharmaceutical compositions comprising these substances and chemical substances for use in such treatment.... Agent: Birch Stewart Kolasch & Birch

20100267740 - Oxadiazole derivatives and their use as metabotropic glutamate receptor potentiators - 842: Compounds of Formula (I) wherein R1 and Q are as described in the specification, pharmaceutically-acceptable salts, methods of making, pharmaceutical compositions containing and methods for using the same.... Agent: Astra Zeneca Pharmaceuticals Lp Global Intellectual Property

20100267741 - Compounds, compositions and methods comprising pyrazole derivatives: The present invention relates to compounds, compositions and methods for treating a disease in an animal, which disease is responsive to inhibiting of functional cystic fibrosis transmembrane conductance regulator (CFTR) polypeptide by administering to a mammal in need thereof an effective amount of a compound defined herein (including those compounds... Agent: Foley & Lardner LLP

20100267742 - Combination targeted therapy for lung cancer: A combination of compounds is described that target protein kinases and is more effective than the individual compounds against cancer where EGFR is upregulated and c-met is activated, for example, epithelial cell tumors, and particularly, non small cell lung carcinomas (NSCLC).... Agent: Barnes & Thornburg LLP

20100267743 - 3-(phenoxypyrrolidin-3-yl-methyl)heteroaryl, 3-(phenylpyrrolidin-3-ylmethoxy)heteroaryl, and 3-(heteroarylpyrrolidin-3-ylmethoxy)heteroaryl compounds: where RA and RB are as defined in the specification, or a pharmaceutically acceptable salt thereof. The compounds of formula I are serotonin and norepinephrine reuptake inhibitors. In another aspect, the invention relates to pharmaceutical compositions comprising such compounds; methods of using such compounds; and process and intermediates for preparing... Agent: Theravance, Inc.

20100267745 - 3-pyridinecarboxamide derivatives as hdl-cholesterol raising agents: e

20100267744 - Pharmaceutical compositions: Forms and formulations of VX-950 and uses thereof.... Agent: Jonathan P. O''brien, Ph.d. Honigman Miller Schwartz & Cohn LLP

20100267746 - Aliphatic pyrazinoylguanidine sodium channel blockers with beta agonist activity: The present invention provides sodium channel blockers possessing beta-adrenergic receptor agonist activity.... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, L.L.P.

20100267747 - 5-(arylsulfonyl)-pyrazolopiperidines: wherein A, B, R1, R1a, R2, R2a, R3 and R3a are as described in the specification. Compounds of Formula I are useful in treating or preventing cognitive disorders, such as Alzheimer's disease. The invention also encompasses pharmaceutical compositions comprising compounds of Formula I, methods of preparing compounds of formula I,... Agent: Mcdonnell Boehnen Hulbert & Berghoff LLP

20100267748 - Heterocyclic compounds useful as stearoyl coa desaturase inhibitors: e

20100267749 - Trisubstituted furopyrimidines and use thereof: The invention relates to the novel 4,5,6-trisubstituted furo[2,3-d]pyrimidine derivatives of formula (I), to methods for their production, their use in the treatment and/or prophylaxis of diseases and their use in the production of drugs for the treatment and/or prophylaxis of diseases, especially for the treatment and/or prophylaxis of cardiovascular diseases.... Agent: Barbara A. Shimei Director, Patents & Licensing

20100267750 - Methods and compositions for treating pain: The present application relates to compounds and methods for treating pain, incontinence and other conditions.... Agent: Lando & Anastasi, LLP

20100267751 - Pharmaceutical compositions and methods of treating dry eye disorders: Inhibitors of Janus kinase-3 (“Jak3”) are useful for treating dry eye disorders and other disorders requiring the wetting of the eye. Jak3 inhibitors useful for treating eye disorders include the compound 3-{(3R,4R)-4-Methyl-3-[methyl-(7H-pyrrolo [2,3-d]pyrimidin-4-yl)-amino]-piperidin-1-yl}-3-oxo-propionitrile.... Agent: Pharmacia Corporation C/o Pfizer Inc.

20100267752 - 3-hydroquinazolin-4-one derivatives for use as stearoyl coa desaturase inhibitors: The present invention discloses 3-hydroquinazolin-4-one derivatives for use as inhibitors of stearoyl-CoA desaturase. The compounds are useful in treating and/or preventing various human diseases, mediated by stearoyl-CoA desaturase (SCD) enzymes, especially diseases related to abnormal lipid levels, cancer, cardiovascular disease, diabetes, obesity, metabolic syndrome and the like.... Agent: Cv Therapeutics, Inc. Gilead Palo Alto, Inc.

20100267753 - Methods of treating disorders associated with protein kinase ck2 activity: e

20100267754 - Integrin expression inhibitor: wherein in the formula, B means a C6-C10 aryl ring or 6- to 10-membered heteroaryl ring which may have a substituent and in which a part of the ring may be saturated; K means a single bond, —CH═CH— or —(CR4bR5b)mb— (wherein R4b and R5b are the same as or different... Agent: Birch Stewart Kolasch & Birch

20100267755 - Pyrimidine derivatives: e

20100267756 - Pharmaceutical preparation for treating demyelinating diseases of the nervous system; preparation promoting restoration of the myelin sheath of nerve fibers; and a method for treating demyelinating diseases of the nervous system: The invention relates to a pharmaceutical remedy used to treat demyelinating diseases of the nervous system, said remedy containing stephaglabrin sulfate that contributes to the restoration of the myelin sheath of nerve fibers, and to a method for treating demyelinating diseases of the nervous system.... Agent: Aleksandr Smushkovich

20100267757 - Aminothiazoles and their uses: The present application describes organic compounds that are useful for the treatment, prevention and/or amelioration of diseases.... Agent: Novartis Institutes For Biomedical Research, Inc.

20100267758 - Pharmaceutical formulation: Stable pharmaceutical compositions useful for administering methylnaltrexone are described, as are methods for making the same. Kits, including these pharmaceutical compositions, also are provided.... Agent: Wolf Greenfield & Sacks, P.C.

20100267759 - Inhibitors of akt activity: Invented are novel heterocyclic carboxamide compounds, the use of such compounds as inhibitors of protein kinase B activity and in the treatment of cancer and arthritis.... Agent: Glaxosmithkline Global Patents -us, Uw2220

20100267760 - Methods of and combination therapies for treating or delaying the onset of dyskinesia: Methods of treating or delaying onset of levodopa-induced dyskinesia in an individual comprise administering to the individual an effective amount of mammalian target of rapamycin (mTOR) inhibitor. Methods of treating or delaying onset of dyskinesia in an individual, wherein the dyskinesia is induced by administration of a drug causing abnormal... Agent: Porter Wright Morris & Arthur, LLP Intellectual Property Group

20100267761 - 7-azaindole derivatives as selective 11-beta-hydroxysteroid dehydrogenase type 1 inhibitors: The present invention relates to 7-azaindole derivatives of formula I as selective inhibitors of the enzyme 11-beta-hydroxysteroid dehydrogenase type 1 (11β-HSD-1) and the use of such compounds for the treatment and prevention of metabolic syndrome, diabetes, insulin resistance, obesity, lipid disorders, glaucoma, osteoporosis, cognitive disorders, anxiety, depression, immune disorders, hypertension... Agent: Millen, White, Zelano & Branigan, P.C.

20100267763 - Method of decreasing pro-adam10 secretase and/or beta secretase levels: The present invention provides a method of decreasing the level of pro-ADAM10 and/or BACE protein in a subject, the method comprising administering a heterocyclic compound or a pharmaceutically acceptable salt, hydrate or prodrug thereof to a subject in need thereof.... Agent: Sterne, Kessler, Goldstein & Fox P.l.l.c.

20100267762 - Novel p2x7r antagonists and their use: The present application is directed to novel P2X7R antagonists that are N-indol-3-yl-acetamide and N-azaindol-3-yl-acetamide compounds, pharmaceutical compositions comprising the same and their use for the prophylactic or therapeutic treatment of diseases mediated by P2X7R activity.... Agent: Cooley LLP Attn: Patent Group

20100267764 - 8-aza-bicyclo[3.2.1]octane derivatives and their use as monoamine neurotransmitter re-uptake inhibitors: e

20100267765 - Pharmaceutical compositions and methods for ccr5 antagonists: The present invention relates to a CCR5 antagonist compound for elevating high density lipoprotein (HDL) particles in a patient, improving plasma lipid profile in a patient or reducing triglycerides in a patient. The invention also relates to a pharmaceutical composition comprising a CCR5 antagonist compound, an HMG-CoA reductase inhibitor compound... Agent: Pfizer Inc. Patent Department

20100267766 - Derivatives of pyrrolizine, indolizine and quinolizine, preparation thereof and therapeutic use thereof: e

20100267767 - Nuclear receptor binding agents: The present invention relates to methods for prevention and/or treatment of metabolic disorders, post-menopausal obesity and conditions associated with high fat diet consumption including, obesity, body weight gain, fat mass formation, bone mineral content reduction, white adipose tissue weight gain, increased cholesterol levels, increased leptin levels, insulin resistance, type II... Agent: Pearl Cohen Zedek Latzer, LLP

20100267768 - Process for making modulators of cystic fibrosis transmembrane conductance regulator: e

20100267769 - Substituted bicyclocarboxyamide compounds:

20100267770 - Piperidine derivatives and cosmetic compositions thereof:

20100267772 - combination of a serotonin reuptake inhibitor and agomelatine: The present invention relates to the use of a combination of agomelatine and a serotonin reuptake inhibitor (SRIs), or any other compound, which causes an elevation in the level of extracellular serotonin, for the treatment of depression and other affective disorders.... Agent: Darby & Darby P.C.

20100267771 - Automated immunossay apparatus with flexible pick-up arm: An automated sample handling apparatus is disclosed having a pipette mechanism (6) which has an integral clamp device (27, 31, 23) suitable for picking up one or more items other than a disposable tip (8; 12) such as a plate holder (35) which can carry a microplate or other consumable... Agent: Donald C Casey

20100267773 - Estrogen receptor ligands and methods of use thereof: The present invention relates to methods of treating androgen deprivation therapy (ADT) induced hot flashes and severe hot flashes in a subject.... Agent: Pearl Cohen Zedek Latzer, LLP

20100267774 - P38 map kinase inhibitors: Compounds of formula (I) are inhibitors of p38 MAP kinase, and are therefore of utility in the treatment of, inter alia, inflammatory conditions including rheumatoid arthritis and COPD: formula (I) wherein: G is —N═ or —CH═; D is an optionally substituted divalent mono- or bi-cyclic aryl or heteroaryl radical having... Agent: Banner & Witcoff, Ltd.

20100267775 - Oxadiazolidinedione compound: A pharmaceutical agent having GPR40 receptor agonistic action, particularly a compound which is useful as an insulin secretagogue or an agent for preventing and/or treating diabetes mellitus. The present inventors have examined a compound having GPR40 receptor agonistic action, confirmed that an oxadiazolidinedione compound which has a substituent such as... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20100267776 - Arylvinylazacycloalkane compounds and methods of preparation and use thereof: Novel vinylazacycloalkane compounds of Formula (I) are disclosed. The compounds are ligands of various nAChRs. The compounds and their pharmaceutically acceptable salts can be used to prepare pharmaceutical compositions and/or medicaments intended to prevent or treat disorders associated with dysfunction of nAChRs, especially within the central nervous system or the... Agent: Womble Carlyle Sandridge & Rice, PLLC

20100267777 - Treatment of cancers with acquired resistance to kit inhibitors: The present invention provides compositions and uses thereof for treating cancers which have acquired resistance to a KIT inhibitor by administering effective amounts of DAST (4{4-[3-(4-chloro-3-trifluoromethylphenyf)-ureido]-3-fluorophenoxy}-pyridine-2-carboxylic acid methylamide.)... Agent: Millen, White, Zelano & Branigan, P.C.

20100267778 - Diphenyl ether compound, process for producing the same, and use: wherein ring A, ring B and ring D each independently represents a cyclic group which may have a substituent(s); W is a spacer having 1 to 8 atom(s) in its main chain; X is a spacer having 1 to 2 atom(s) in its main chain; Y is a binding bond... Agent: Sughrue Mion, PLLC

20100267780 - Bicyclic aryl and heteroaryl receptor modulators: Compounds of formula (I) or pharmaceutically acceptable salts thereof, are opioid receptor modulators, e.g. mu-opioid receptor antagonists, neutral antagonists or inverse agonists, and are useful inter alia for the treatment of obesity.... Agent: Osi Pharmaceuticals, Inc.

20100267779 - Novel compounds and methods of using them: Described herein are novel HDAC inhibitors, formulations containing them and methods of using them. In some embodiments, the HDAC inhibitors possess specific stereochemistry. In other embodiments, the compounds described herein are used in the treatment or prevention of histone deacetylase mediated disorders.... Agent: Wilson, Sonsini, Goodrich & Rosati

20100267781 - Naphthalene-based inhibitors of anti-apoptotic proteins: s

20100267782 - Sodium channel inhibitors: Compounds, compositions and methods are provided which are useful in the treatment of diseases through the inhibition of sodium ion flux through voltage-gated sodium channels. More particularly, the invention provides substituted aryl sulfonamides, compositions comprising these compounds, as well as methods of using these compounds or compositions in the treatment... Agent: Townsend And Townsend And Crew, LLP

20100267783 - Pharmaceutical composition containing optically active compound having thrombopoietin receptor agonist activity, and intermediate therefor: m

20100267784 - Novel 4,5-dihydroisoxazoles with estrogenic activity: This invention relates to novel 4,5-dihydroisoxazoles of formula (I), to their use as estrogen receptor modulators, and to methods of their preparation.... Agent: Birch Stewart Kolasch & Birch

20100267785 - Candesartan cilexetil: Candesartan cilexetil-containing granules which include a sugar alcohol and a binder and which are produced by granulation with an alcoholic granulating liquid. The granules are suitable for producing tablets in which the candesartan cilexetil is present in a form stabilized with regard to decomposition.... Agent: Lerner, David, Littenberg, Krumholz & Mentlik

20100267786 - Dual acting pharmaceutical compositions based on superstructures of angiotensin receptor antagonist/blocker (arb) and ne utral endopeptidase (ep) inhibitor: Solid oral dosage forms, especially tablets, of a pharmaceutical composition comprising a supramolecular complex can be formed from a direct compression process or a compaction process such as roller compaction. Such solid oral dosage forms feature an immediate release profile that allows for fast release of the therapeutic agent. A... Agent: Novartis Corporate Intellectual Property

20100267788 - Dual-acting antihypertensive agents: wherein Ar, r, R3, X, and R5-7 are as defined in the specification, and pharmaceutically acceptable salts thereof. The compounds of formula I have AT1 receptor antagonist activity and neprilysin inhibition activity. The invention is also directed to pharmaceutical compositions comprising such compounds; methods of using such compounds; and a... Agent: Theravance, Inc.

20100267787 - Pharmaceutical compositions: Provided are compositions comprising aqueous solutions of valsartan suitable for oral administration, preferably in pediatric and geriatric populations. Methods for making such compositions and methods for their stabilization are provided.... Agent: Novartis Corporate Intellectual Property

20100267789 - Tablet formulations comprising valsartan: The invention relates to solid oral dosage forms comprising pharmacologically effective amounts of valsartan or a pharmaceutically acceptable salt thereof or hydrate thereof. The compositions are at least 1.2 times more bioavailable than conventional valsartan capsule.... Agent: Novartis Corporate Intellectual Property

20100267790 - Method, use and agent for protecting a plant against phakopsora: The present invention relates to a method for protecting a plant against a phytopathogen selected from the genus Phakopsora, wherein the seed of the plant is treated with (a) prothioconazole or a salt or adduct thereof and (b) trifloxystrobin or a salt or adduct thereof.... Agent: Brinks, Hofer, Gilson & Lione

20100267791 - Method for preventing growth of microorganisms, and a combination for the prevention of microbial growth: According to the invention, a method for the prevention of microbial growth in process waters is provided, wherein first a peracid compound, and thereafter a halogenated dialkyl hydantoin are dosed into said process water. Further, according to the invention, a combination for the prevention of microbial growth is provided, said... Agent: Cantor Colburn, LLP

20100267792 - Topical compositions containing desthiobiotin and its derivatives and a method of treating skin: Topical compositions and methods of use to treat symptoms of reduced skin elasticity are provided comprising desthiobiotin and certain desthiobiotin analogues. These compounds are effective in stimulating LOXL-1 activity and can thus increase elastin remodeling and improve appearance of fine lines, wrinkles, skin sagging and other symptoms of reduced elastin... Agent: Avon Products, Inc.

20100267793 - Method of treatment using n3 alkylated benzimidazole derivatives as mek inhibitors: p

20100267794 - Anti-fatigue agent comprising amino acid composition: Conventional amino acid compositions are primarily intended to improve athletic performance or to promote fat-burning. Provided is an anti-fatigue agent which can prevent both of muscle fatigue and nerve strain concurrently. An anti-fatigue agent which comprises an amino acid composition composed of specific amino acids in specified amounts can prevent... Agent: Edwards Angell Palmer & Dodge LLP

20100267795 - Nitrosubstituted aryloxyalkylimidazolines for use as pesticides: The present invention relates to imidazoline derivatives and their use as insecticidal and acaricidal agents. The invention also extends to insecticidal and acaricidal compositions comprising such imidazoline derivatives, and to methods of using such derivatives and/or compositions to combat and control insect and acarine pests. In particular the present invention... Agent: Syngenta Crop Protection , Inc. Patent And Trademark Department

20100267796 - Therapeutic agent for irritable bowel syndrome: e

20100267797 - Use of tetramic acid derivatives for controlling pests by watering or droplet application:

20100267799 - Orodispersible pharmaceutical composition of perindopril: The invention relates to a solid orodispersible pharmaceutical composition of perindopril, characterised in that it comprises perindopril or a pharmaceutically acceptable salt thereof and granules consisting of co-dried lactose and starch.... Agent: The Firm Of Hueschen And Sage

20100267798 - Pharmaceutical formulations and use thereof in the prevention of stroke, diabetes and/or congestive heart failure: The present invention relates to use of an inhibitor of the renin-angiotensin system (RAS) or a pharmaceutically acceptable derivative thereof, such as ramipril or ramiprilat, in the prevention of stroke, diabetes and/or congestive heart failure (CHF).... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20100267800 - N-alkyl-hydroxamic acid-isoindolyl compounds and their pharmaceutical uses: The invention encompasses novel N-alkyl-hydroxamic acid-isoindolyl compounds, pharmaceutical compositions of these compounds, and methods of using these compounds and compositions for treatment or prevention of various diseases and disorders, for example, diseases associated with PDE4.... Agent: Jones Day

20100267817 - Lyophilized pharmaceutical composition with improved reconstitution time containing taxane derivatives and method of manufacturing the same: The present invention relates to a lyophilized composition with an improved reconstitution time comprising a taxoid and a method thereof. More specifically, the present invention relates to a lyophilized composition with an improved reconstitution time prepared by mixing and dissolving a taxoid; cyclodextrin (CD); a hydrophilic polymer selected from the... Agent: Frommer Lawrence & Haug

20100267818 - Stabilized single-liquid pharmaceutical composition containing docetaxel: This invention relates to a single-liquid pharmaceutical composition for injection containing docetaxel. The composition includes (A) docetaxel and pharmaceutically acceptable salts thereof, (B) a surfactant selected from the group consisting of polysorbate, polyoxyethylene glycol ester and polyoxyethylene castor oil derivatives, (C) a solvent comprising anhydrous ethanol in a concentration range... Agent: Sughrue Mion, PLLC

20100267819 - Pharmaceutical composition for diabetic nephropathy and its preparation and application: The invention relates to a pharmaceutical composition for diabetic nephropathy and its preparation, and the application in preparing of medicine for diabetic nephropathy. The pharmaceutical composition is made up of at least one of 7-hydroxycoumarin and 7-hydroxy-6-methoxycoumarin as active ingredient, and the weight percentage of active ingredient is 0.1-99.5%. Moreover,... Agent: Edwards Angell Palmer & Dodge LLP

20100267820 - Antiadhesion agents: e

20100267821 - Prophylactic or therapeutic agent for irritable bowel syndrome:

20100267822 - Aurones as estrogen receptor modulators and their use in sex hormone dependent diseases: The invention relates to aurones and extracts comprising them useful in the prophylactic and/or therapeutic treatment of an animal (including a human) with an estrogen receptor (ER) related disease or condition of the animal or human body, as well as methods, uses and other inventions related thereto.... Agent: Patterson Thuente Christensen Pedersen, P.A.

20100267823 - Aurones as selective pde inhibitors and their use in neurological conditions and disorders: The invention relates to aurones and extracts comprising them useful in the prophylactic and/or therapeutic treatment of an animal (including a human) with a phosphodiesterase (PDE) dependent disease or condition of the central nervous system, as well as methods, uses and other inventions related thereto.... Agent: Patterson Thuente Christensen Pedersen, P.A.

20100267824 - Stable oxaliplatin composition for parenteral administration: The present invention relates to a stable parenteral composition of oxaliplatin having pH range in between 3 to 4.5, which comprises of a solution of oxaliplatin in water wherein the said pH is attained by sparging of carbon dioxide in the composition. Further, a method for the preparation of oxaliplatin... Agent: Hamre, Schumann, Mueller & Larson, P.C.

20100267825 - Treatment of skin damage: Methods and apparatus are disclosed for diagnosing and treating oxidative skin damage in a subject. The therapeutic method can comprise: (i) diagnosing a level of oxidative skin damage in a sample comprising stratum corneum of the subject; and (ii) recommending a therapeutic regime for treatment of oxidative skin damage in... Agent: Nutter Mcclennen & Fish LLP

20100267826 - Treatment of ischemic episodes and cerebroprotection through prostaglandin e2 (pge2) ep2 and/or ep4 receptor agonists: The present invention provides compositions and methods for treating an ischemic episode using PGE2 EP2 agonists and/or PGE2 EP4 agonists alone or in combination with anti-thrombotic agents.... Agent: Stanford University

20100267827 - Phenyl-prenyl-ether derivatives for the treatment of cognitive, neurodegenerative or neuronal diseases or disorders: The present invention is related to a family of phenyl-prenyl-ether derivatives of formula (I), and to their use in the treatment of cognitive, neurodegenerative or neuronal diseases or disorders, such as Alzheimer's disease or 5 Parkinson's Disease. The present invention also relates to pharmaceutical compositions comprising the same. Further, the... Agent: Hoffmann & Baron, LLP

20100267828 - dha derivatives and their use as medicaments: and their use as medicaments for the treatment of various diseases and conditions, for example, reduction of elevated triglyceride levels, i.e., hypertriglyceridemia, reduction of non-HDL cholesterol, reduction of glucose and HbA1c, and improvement of insulin resistance. The present disclosure also relates to a pharmaceutical composition comprising compounds of formula (I),... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20100267829 - Pharmaceutical composition comprising low concentrations of environment pollutants: The invention relates to a process for decreasing the amount of environmental pollutants in a mixture comprising a fat or an oil, being edible or for use in cosmetics, the fat or oil containing the environmental pollutants, which process comprises the steps of adding a volatile working fluid to the... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20100267830 - Methods and compositions for promoting the neurological development of an infant: The present invention relates to methods for promoting the neurological development of an infant by administration of fatty acids and compositions comprising same, wherein the fatty acids are enriched with respect to docosahexaenoic acid (DHA) content.... Agent: Morris Manning Martin LLP

20100267831 - Amino acid-containing composition for preventing or remedying decrease in the skeletal muscle of aged people: The present invention provides an amino acid-containing composition for preventing or remedying a decrease in skeletal muscle mass of aged people, comprising L-leucine at a molar composition ratio of 35% or more with respect to total of essential amino acids. According to the invention, the protein anabolism of skeletal muscle... Agent: Cermak Nakajima LLP Acs LLC

20100267832 - Method for treating macular degeneration: Disclosed is a method for treating macular degeneration in a mammalian subject, which comprises administering to the subject in need thereof an effective amount of a 15-keto-prostaglandin compound such as 13,14-dihydro-15-keto-20-ethyl-prostaglandin F2α isopropyl ester.... Agent: Sughrue Mion, PLLC

20100267833 - Compositions and methods for preventing or treating an inflammatory response: The present invention relates to methods for modulating the inflammatory response of respiratory tract cells using an agent that increases ceramide levels in the cells of the respiratory tract.... Agent: Licata & Tyrrell P.C.

20100267834 - Methods and pharmaceutical compositions for differentially altering gene expression to provide neuroprotection for the animal central nervous system against the effects of ischemia, neurodegeneration, trauma and metal poisoning: Pharmaceutical compositions for treating and/or pre-treating or preconditioning the animal central nervous system against the effects of Alzheimer's Disease including the associated neurodegeneration and cognitive, behavioral and physical impairments. In one embodiment, an effective dose of deferoxamine (DFO) is administered to the upper one-third of the subject patient's nasal cavity... Agent: Altera Law Group, LLC

20100267835 - Methods of treating disorders of trigeminalvascular activation: Alpha-aminoamide derivatives useful in the treatment of disorders of trigeminalvascular activation are disclosed.... Agent: Dechert LLP

20100267836 - Novel melatonin ligands having antidepressant activity as well as sleep inducing properties: R is selected from the group consisting of hydrogen, hydroxyl, —OCF3, CF3, C1-C8 alkyl, C1-C8 alkyloxy, C1-C8 alkylthio, halogen and —Z—(CH2)p-A; R1 is selected from the group consisting of C1-C4 alkyl, C3-C6 cycloalkyl, CF3, hydroxy-substituted C1-C4 alkyl, hydroxy-substituted C3-C8 cycloalkyl, and NHR5, wherein R5 is C1-C3 alkyl or C3-C6 cycloalkyl;... Agent: Fulbright & Jaworski L.L.P.

20100267837 - Use of at least one oxime derivative of 3,5-seco-4-nor-cholestane as antioxidants: The invention relates to the use of at least one oxime derivative of 3,5-seco-4-norcholestane as antioxidants in the cosmetics and food fields, and as antioxidant preservatives that can be used, in particular, in cosmetic, food and pharmaceutical products.... Agent: Browdy And Neimark, P.l.l.c. 624 Ninth Street, Nw

20100267838 - Pulverulent carotenoid preparation for colouring drinks: The present invention relates to pulverulent compositions of at least one carotenoid selected from the group consisting of β-carotene, astaxanthin, canthaxanthin, citranaxanthin, lycopene and lutein, a process for the production of these pulverulent compositions, and the use of the pulverulent compositions.... Agent: Connolly Bove Lodge & Hutz, LLP

20100267839 - Diarylalkanes as potent inhibitors of binuclear enzymes: The present invention implements a strategy that combines an enzyme inhibition assay with a chemical dereplication process to identify active plant extracts and the particular compounds—diarylalkanes and/or diarylalkanols within those extracts that specifically inhibit binuclear enzyme function. Included in the present invention are compositions of matter comprised of one or... Agent: Swanson & Bratschun, L.L.C.

20100267840 - Stabilizers for hydrophobic components in personal care compositions: The present invention provides personal care compositions, as well as methods for stabilizing a degradable of reactive hydrophobic, cosmetically acceptable, component in an aqueous composition.... Agent: The Dow Chemical Company

20100267841 - Composition for topical use containing an extract of stryphnodendron; its preparation as well as its application: The present invention relates to topical compositions containing extracts of the plant genus Stryphnodendron as well as their preparation and application. The compositions contain between 1% and 6% of total phenols and are useful for the treatment of cutaneous wounds.... Agent: Smith Hopen, Pa

20100267842 - Emulsions of perfluorocarbons: The subject application provides for an emulsion comprising an amount of a perfluorocarbon liquid dispersed as particles within, a continuous liquid phase, wherein the dispersed particles have a monomodal particle size distribution and uses thereof. The subject application also provides for a method of manufacturing a perfluorocarbon emulsion, a process... Agent: Cooper & Dunham, LLP

20100267844 - Alkylene oxide-capped secondary alcohol alkoxylates useful as surfactants: Disclosed are compositions of the formula wherein R1 and R2 are each independently hydrogen or a linear or branched alkyl group containing from (1) to about (18) carbon atoms, provided that R1 and R2 together contain from about (8) to about (18) carbon atoms, and further provided that less than... Agent: The Dow Chemical Company

20100267843 - Mixed fluoroalkyl-alkyl surfactants: s

20100267845 - (meth)acrylic acid/alkyl (meth)acrylate ester copolymer and cosmetic preparation containing the same: A (meth)acrylic acid/alkyl (meth)acrylate ester copolymer containing constituents of 95.42 to 97.48% by mass of (meth)acrylic acid, 2.43 to 4.30% by mass of an alkyl (meth)acrylate ester of which alkyl group has 18 to 24 carbon atoms, and 0.08 to 0.30% by mass of a compound having two or more... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, L.L.P.

20100267846 - Molecular delivery vehicle: An isolated caveolin containing vesicle comprising a caveolin protein and at least one lipid, wherein at least about 30% of the at least one lipid is selected from phosphatidylethanolamine and phosphatidylglycerol is disclosed. Also disclosed is a method of making an isolated caveolin containing vesicle, an isolated caveolin containing vesicle... Agent: Joseph R. Baker, Apc Gavrilovich, Dodd & Lindsey LLP

20100267847 - Method of improving sweetness qualities of stevia extract: The present invention provides a technique for improving the sweetness of stevia extract. A composition having an excellent sweetness quality can be obtained by combining rebaudioside A, which is a main sweetness component of stevia extract, with mogroside V, which is a main sweetness component of siraitia grosvenorii extract, at... Agent: Kratz, Quintos & Hanson, LLP

- None available for 10/01/2010

- None available for 10/7/2010

Previous industry: Perfume compositions
Next industry: Colloid systems and wetting agents; subcombinations thereof; processes of


######

RSS FEED for 20140410: xml
Integrate FreshPatents.com into your RSS reader/aggregator or website to track weekly updates.
For more info, read this article.

######

Thank you for viewing Drug, bio-affecting and body treating compositions patents on the FreshPatents.com website. These are patent applications which have been filed in the United States. There are a variety ways to browse Drug, bio-affecting and body treating compositions patent applications on our website including browsing by date, agent, inventor, and industry. If you are interested in receiving occasional emails regarding Drug, bio-affecting and body treating compositions patents we recommend signing up for free keyword monitoring by email.



Results in 4.02236 seconds

PATENT INFO